{"title":"Epidemiology and Medical statistics Books","description":"","products":[{"product_id":"statistics-and-informatics-in-molecular-cancer-research-9780199532872","title":"Statistics and Informatics in Molecular Cancer","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eMolecular understanding of cancer and cancer progression is at the forefront of many research programs today. High-throughput array technologies and other modern molecular techniques produce a wealth of molecular data about the structure, and function of cells, tissues, and organisms. Correctly analyzed and interpreted these data hold the promise of bringing new markers for prognostic and diagnostic use, for new treatment schemes, and of gaining new biological insight into the evolution of cancer and its molecular, pathological, and clinical consequences.Aimed at graduates and researchers, this book discusses novel advances in informatics and statistics in molecular cancer research. Through eight chapters from carefully chosen experts it brings the reader up to date with specific topics in cancer research, how the topics give rise to development of new informatics and statistics tools, and how the tools can be applied. The focus of the book is to give the reader an understanding of key\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePREFACE ; 1. Association Studies ; 2. Methods for DNA Copy Number Derivations ; 3. Methods for Derivation of LOH and Allelic Copy Numbers Using SNP Arrays ; 4. Bioinformatics of gene expression and copy number data integration ; 5. Analysis of DNA Methylation in Cancer ; 6. Pathway Analysis: Pathway Signatures and Classification ; 7. Two Methods for Comparing Genomic Data Across Independent Studies in Cancer Research: Meta-analysis and Oncomine Concepts Map ; 8. Bioinformatic Approaches to the Analysis of Alternative Splicing Variants in Cancer Biology ; INDEX","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":47832696979799,"sku":"9780199532872","price":49.5,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780199532872.jpg?v=1710336900"},{"product_id":"duty-of-care-this-is-the-book-everyone-should-read-about-covid-19-kate-mosse-9781787395596","title":"Duty of Care: 'This is the book everyone should","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e'Beautifully written, passionate and moving, this is the book everyone should read about COVID-19' Kate Mosse\u003c\/p\u003e\u003cp\u003e'Hard to put down' Rachel Clarke\u003c\/p\u003e\u003cp\u003e'Gripping, humane, eye-opening and seriously tense' Ian Dunt\u003c\/p\u003e\u003cp\u003eThe first book to tell the full story of the COVID-19 pandemic from a doctor on the frontline.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eALL ROYALTIES FROM SALES GO TO HEROES, A CHARITY PROTECTING AND SUPPORTING HEALTHCARE WORKERS. \u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eOn the 8th of February, Dr Dominic Pimenta encountered his first suspected case of coronavirus. Within a week, he began wearing a mask on the tube, and within a month, he moved over to the Intensive Care Unit to help fight the virus.\u003c\/p\u003e\u003cp\u003eFrom the initial whispers coming out of China and the collective hesitation to class this as a pandemic to full lockdown and the continued battle to treat whoever came through the doors, Dr Pimenta tells the heroic stories of how the entire system shifted to tackle this outbreak and how, ultimately, the staff managed to save lives.\u003c\/p\u003e\u003cp\u003eThis incredible account captures the shock and surprise, the panic and power of an unprecedented time, and how, at this moment of despair, human generosity and kindness prevailed.\u003c\/p\u003e\u003cp\u003e'A startlingly personal account ... It can be described as a memoir, a thriller or a horror story, but it is really all at once' \u003ci\u003eObserver\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e'Reads like a thriller – a first-hand account of a group of individuals facing a terrible adversary – but it also moved me sometimes to tears because it communicates the humanity of the patients, as well as the NHS staff. As with all great writing, its honesty shines out' Tim Walker\u003c\/p\u003e\u003cp\u003e'An excellent book ... Moving and fascinating in equal measure' Xand van Tulleken\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'Duty of Care is a tense and gripping account of the unfolding pandemic from a doctor who was there. The bravery and dedication of NHS staff are extraordinary, the looming dangers vividly described. I found it hard to put down' -- Dr Rachel Clarke, Sunday Times bestselling author of Dear Life and Your Life in My Hands.\u003cbr\u003e'Gripping, humane, eye-opening and seriously tense. Public interest journalism which reads like a thriller novel' -- Ian Dunt.\u003cbr\u003e'Truly wonderful ... Brilliant at explaining what it means to be at the heart of things, the growing sense of menace ... Absolutely essential reading ... It deserves to be on every recommended reading list and pressed into the hands of every politician ... Beautifully written, passionate and moving, this is the book everyone should read about COVID-19' -- Kate Mosse.\u003cbr\u003e'A startlingly personal account ... It can be described as a memoir, a thriller or a horror story, but it is really all at once' * Observer. *\u003cbr\u003e'Reads like a thriller – a first-hand account of a group of individuals facing a terrible adversary – but it also moved me sometimes to tears because it communicates the humanity of the patients, as well as the NHS staff. As with all great writing, its honesty shines out' -- Tim Walker.\u003cbr\u003e'An excellent book ... Moving and fascinating in equal measure' -- Xand van Tulleken.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e0\u003c\/p\u003e","brand":"Headline Publishing Group","offers":[{"title":"Default Title","offer_id":47851104731479,"sku":"9781787395596","price":8.54,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781787395596.jpg?v=1710629667"},{"product_id":"crash-landing-the-inside-story-of-how-the-worlds-biggest-companies-survived-an-economy-on-the-brink-9781529355734","title":"Crash Landing: The Inside Story Of How The","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eIt was the ultimate test for CEOs, and almost none of them saw it coming.\u003c\/b\u003e\u003cbr\u003e\u003cb\u003e__________\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003eIn early March 2020, with the Dow Jones flirting with 30,000, the world's biggest companies were riding an eleven-year economic high. By the end of the month, millions would be out of work, iconic firms were begging for bailouts, and countless small businesses were in freefall. Slick consulting teams and country-club connections were suddenly of little use: business leaders were fumbling in the dark, tossing out long-term strategy and making decisions on the fly-decisions, they hoped, that might just save them.\u003cbr\u003e\u003cbr\u003eIn \u003ci\u003eCrash Landing\u003c\/i\u003e, award-winning business journalist Liz Hoffman shows how the pandemic set the economy on fire-but if you look closely, the tinder was already there.\u003cbr\u003e\u003cbr\u003eBased on astonishing access inside some of the world's biggest and most iconic companies, this is a gripping account of the most remarkable period in modern economic history, revealing how they battled against an economic catastrophe for which there was no playbook: among them, AirBnB's Brian Chesky, blindsided by a virus in the middle of a high-stakes effort to go public; American Airlines's Doug Parker, shuttling between K Street and the White House, determined to secure a multi-billion-dollar bailout; and Ford's Jim Hackett, as his assembly lines went from churning out cars to ventilators.\u003cbr\u003e\u003cbr\u003e\u003ci\u003eCrash Landing\u003c\/i\u003e reveals the fear, grit, and gambles of the pandemic economy, while probing its implications for the future of work, corporate leadership, and capitalism itself, asking: Will this remarkable time give rise to newfound resilience, or become just another\u003cbr\u003ecostly mistake to be forgotten?\u003cbr\u003e\u003cb\u003e__________\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eA gripping account of the financial carnage of the pandemic, revealing the fear, grit, and gambles that drove the economy's winners and losers. \u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'With the urgency of \u003ci\u003eToo Big to Fail\u003c\/i\u003e and unforgettable characterizations of \u003ci\u003eThe Big Short\u003c\/i\u003e, Crash Landing tells a momentous story: how the Covid-19 pandemic threatened not just billions of lives but the livelihoods and economic safety of nearly everyone on the planet.' -- \u003cb\u003eBrad Stone, author of \u003ci\u003eAmazon Unbound\u003c\/i\u003e and \u003ci\u003eThe Everything Store\u003c\/i\u003e\u003c\/b\u003e\u003cbr\u003e\"Hoffman takes readers behind the scenes to show how corporate, business and government leaders responded to a once-in-century calamity. \u003ci\u003eCrash Landing\u003c\/i\u003e is full of drama. Those eager to prepare for the next crisis should read this book and heed its lessons.\" \u003cb\u003e--Gregory Zuckerman, \u003ci\u003eNew York Times\u003c\/i\u003e bestselling author of \u003ci\u003eThe Man Who Solved the Market\u003c\/i\u003e\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\"\u003ci\u003eCrash Landing\u003c\/i\u003e is a true masterwork. Liz Hoffman's perceptive, well researched, and captivating look at how COVID transformed the business and financial industries should be on the shelf of every student of the business world.\"\u003cbr\u003e\u003cb\u003e--David Rubenstein, co-founder and co-chairman, The Carlyle Group; New York Times bestselling author of How to Invest\u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e\"A rare look inside the split -second, high-stakes decisions at the top of America's corporate giants. This book reflects Liz Hoffman's rare combination of valuable gifts: vivid writing, incredible access and sourcing, and actual insight.\" \u003cb\u003e-- Mary Childs, author of national bestseller The Bond King, cohost of NPR's \"Planet Money\"\u003c\/b\u003e\u003cbr\u003e\"There is a reason Liz Hoffman is known in journalism circles as a scoop machine: she gets people to talk. In \u003ci\u003eCrash Landing\u003c\/i\u003e she takes us inside the heads of the business world's biggest power players as they stare at an economic abyss. The result is a riveting chronicle of the boardroom brinksmanship that-mostly-succeeded, but also how this unprecedented era exposed new risks and thrust an uncomfortable spotlight on the role of corporate leaders that will endure.\" \u003cb\u003e--Bradley Hope, \u003ci\u003eNew York Times\u003c\/i\u003e bestselling author of \u003ci\u003eBillion Dollar Whale\u003c\/i\u003e and \u003ci\u003eThe Rebel and the Kingdom\u003c\/i\u003e\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e'This book reads like a suspense thriller, because that's what it is, even though every word is true. Hoffman casts her brilliant reportorial eye on the economic upheaval that began in late 2019. She reveals just how often the supposed rational leaders of the economy are actually shooting from the hip, relying on gut instinct, cronyism and self-interest to try and steer the economy away from the abyss.' \u003cb\u003e-- Brian Koppelman, co-creator, showrunner, and executive producer of Showtime's \u003ci\u003eBillions\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e'In \u003ci\u003eCrash Landing\u003c\/i\u003e, Liz Hoffman offers something fresh and much-needed: an insider tale of what it takes to steer a company-indeed, an economy-through a shock that nobody saw coming. Having spent time in boardrooms in times of crisis, the portrait she paints is highly accurate. The aspiring C-suite class should take note.' \u003cb\u003e-- Harvey Schwartz, former president and co-chief operating officer, Goldman Sachs\u003c\/b\u003e","brand":"Hodder \u0026 Stoughton","offers":[{"title":"Default Title","offer_id":47851541922135,"sku":"9781529355734","price":19.79,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781529355734.jpg?v=1710638730"},{"product_id":"the-ghost-map-9780141029368","title":"The Ghost Map","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eFrom the bestselling author of \u003ci\u003eEverything Bad is Good For You\u003c\/i\u003e, Steven Johnson''s \u003ci\u003eThe Ghost Map \u003c\/i\u003evividly recreates Victorian London to show how huge populations live together, how cities can kill - and how they can save us.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e  Steven Johnson is one of today''s most exciting writers about popular culture, urban living and new technology. In \u003ci\u003eThe Ghost Map\u003c\/i\u003e he tells the story of the terrifying cholera epidemic that engulfed London in 1854, and the two unlikely heroes - anesthetist Doctor John Snow and affable clergyman Reverend Henry Whitehead - who defeated the disease through a combination of local knowledge, scientific research and map-making.\u003cbr\u003e\u003cbr\u003e  In telling their extraordinary story, Steven Johnson also explores a whole world of ideas and connections, from urban terror to microbes, ecosystems to the Great Stink, cultural phenomena to street life.\u003cbr\u003e\u003cbr\u003e  ''A wonderful book''\u003cbr\u003e  \u003ci\u003eMail on Sunday\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e  ''A thumping page-turne\u003c\/p\u003e","brand":"Penguin Books Ltd","offers":[{"title":"Default Title","offer_id":48732398125399,"sku":"9780141029368","price":10.44,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780141029368.jpg?v=1719996705"},{"product_id":"cdc-yellow-book-2018-health-information-for-international-travel-9780190628611","title":"CDC Yellow Book 2018 Health Information for","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eTHE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world.The fully revised and updated 2018 edition codifies the U.S. government''s most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities Special considerations for ne\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e[The CDC Yellow BooK 2018] is a truly excellent and comprehensive resource * Andrew Berrington, Journal of Hospital Infection *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Boxes, Figures, Maps, and Tables, by Topic   List of Maps      Editorial Staff        CDC Contributors       External Contributors     Acknowledgments       In Memoriam: Dedication to Alan J. Magill     Preface          1. Introduction        Introduction to Travel Health \u0026amp; the Yellow Book    Planning for Healthy Travel: CDC Travelers' Health Website and Mobile Applications  Travel Epidemiology       Perspectives: The Role of the Traveler in Translocation of Disease  Perspectives: Why Guidelines Differ       Air Travel Trends          2. The Pre-Travel Consultation      The Pre-travel Consultation       Perspectives: Travelers' Perception of Risk      Perspectives: Prioritizing Care for the Resource-Limited Traveler   Perspectives: The Need for a Cost Analysis of to Justify the Travel MedicineConsult    General Recommendations for Vaccination \u0026amp; Immunoprophylaxis   Interactions among Travel Vaccines \u0026amp; Drugs  Perspectives: Fear of Vaccines  Self-Treatable Conditions        Travelers' Diarrhea         Perspectives: Antibiotics in Travelers' Diarrhea -- Balancing the Risks \u0026amp; Benefits For the Record: A History of the Definition \u0026amp; Management of Travelers' Diarrhea Altitude Illness         For the Record: A History of the Definition \u0026amp; Management of Altitude Illness Jet Lag           Motion Sickness         Respiratory Infections        Counseling \u0026amp; Advice for Travelers       Food \u0026amp; Water Precautions  Perspectives: Prevention of Travelers' Diarrhea-It's Not Only WHAT You Eat \u0026amp; Drink            Water Disinfection for Travelers     Food Poisoning from Marine Toxins       Protection against Mosquitoes, Ticks, \u0026amp; Other Arthropods    Sun Exposure          Problems with Heat \u0026amp; Cold        Injury Prevention       Safety \u0026amp; Security         Animal-Associated Hazards        Natural Disasters  Environmental Hazards        Scuba Diving          Medical Tourism         Discussing Complementary and\/or Alternative Integrative Health Approaches with Travelers    Deep Vein Thrombosis \u0026amp; Pulmonary Embolism     Mental Health          Travel Health Kits         Perspectives: Pharmaceutical Quality \u0026amp; Counterfeit Falsified Drugs   Obtaining Health Care Abroad for the Ill Traveler       Travel Insurance, Travel Health Insurance, \u0026amp; Medical Evacuation Insurance    3. Infectious Diseases Related to Travel     Amebiasis          Angiostrongyliasis, Neurologic  Anthrax  B virus  Bartonella Infections         Brucellosis          Campylobacteriosis         Chikungunya         Cholera          Coccidioidomycosis        Cryptosporidiosis         Cutaneous Larva Migrans        Cyclosporiasis          Cysticercosis          Dengue         Diphtheria  Ebola Virus Disease and Marburg Virus Disease   Echinococcosis        Escherichia coli, Diarrheagenic         Fascioliasis          Filariasis, Lymphatic       Giardiasis  Hand, Foot, \u0026amp; Mouth Disease  Helicobacter pylori         Helminths, Soil-Transmitted        Hepatitis A          Hepatitis B          Hepatitis C          Hepatitis E          Histoplasmosis         HIV Infection          Influenza  Japanese Encephalitis  Legionellosis (Legionnaires' Disease \u0026amp; Pontiac Fever)    Leishmaniasis, Cutaneous        Leishmaniasis, Visceral        Leptospirosis          Lyme Disease          Malaria         For the Record: A History of Malaria Chemoprophylaxis  Measles (Rubeola)  Melioidosis  Meningococcal Disease        Middle East Respiratory Syndrome (MERS)     Mumps       Norovirus         Onchocerciasis (River Blindness)  Pertussis Pinworm (Enterobiasis, Oxyuriasis, Threadworm)     Plague (Bubonic, Pneumonic, Septicemic)      Pneumococcal Disease        Poliomyelitis        For the Record: A History of Polio Eradication Efforts    Q Fever          Rabies         Perspectives: Intradermal Rabies Preexposure Immunization  Rickettsial (Spotted \u0026amp; Typhus Fevers) \u0026amp; Related Infections, including Anaplasmosis \u0026amp; Ehrlichiosis  Rubella         Salmonellosis (Nontyphoidal)  Sarcocystosis          Scabies          Schistosomiasis       Sexually Transmitted Diseases      Perspectives: Sex \u0026amp; Tourism       Shigellosis          Smallpox \u0026amp; Other Orthopoxvirus-Associated Infections  Strongyloidiasis         Taeniasis         Tetanus          Tickborne Encephalitis     Toxoplasmosis  Trypanosomiasis, African (Sleeping Sickness) Trypanosomiasis, American (Chagas Disease)  Tuberculosis  Perspectives: Tuberculin Skin Testing of Travelers    Typhoid \u0026amp; Paratyphoid Fever       Varicella (Chickenpox)        Viral Hemorrhagic Fevers        Yellow Fever         For the Record: A History of Yellow Fever Vaccine Requirements   Yersiniosis          Zika Virus          Yellow Fever \u0026amp; Malaria Information, by Country      4. Select Destinations        Rationale for Select Destinations      Africa \u0026amp; The Middle East         East Africa: Safaris         Saudi Arabia: Hajj\/Umrah Pilgrimage       South Africa          Tanzania: Kilimanjaro        The Americas \u0026amp; The Caribbean       Brazil         Cuba Dominican Republic        Haiti          Mexico          Peru: Cusco-, Machu Picchu, and Other Regions        Asia         Burma (Myanmar) Cambodia          China           India  Nepal           Thailand          Vietnam  The Middle East \u0026amp; North Africa  Egypt \u0026amp; Nile River Cruises  Saudi Arabia: Hajj Pilgrimage       5. Post-Travel Evaluation       General Approach to the Returned Traveler     Fever in Returned Travelers        Persistent Travelers' Diarrhea        Skin \u0026amp; Soft Tissue Infections in Returned Travelers     Screening Asymptomatic Returned Travelers      6. Conveyance \u0026amp; Transportation Issues     Air Travel          Cruise Ship Travel  Perspectives: What to Expect when Traveling during an International Outbreak Death during Travel  Taking Animals \u0026amp; Animal Products across International Borders   7. International Travel with Infants \u0026amp; Children    Traveling Safely with Infants \u0026amp; Children      Vaccine Recommendations for Infants \u0026amp; Children     Travel \u0026amp; Breastfeeding       International Adoption         8. Advising Travelers with Specific Needs   Immunocompromised Travelers  Travelers with Chronic Illnesses Pregnant Travelers        Travelers with Disabilities  Immigrants Returning Home to Visit Friends \u0026amp; Relatives (VFRs)  Health Care Workers      Advice for Air Crews         Humanitarian Aid Workers        Long-Term Travelers \u0026amp; Expatriates     Perspectives: Malaria in Long-Term Travelers \u0026amp; Expatriates  Last-Minute Travelers  Special Considerations for US Military Deployments    Study Abroad \u0026amp; Other International Student Travel  Travel to Mass Gatherings        Newly Arrived Immigrants \u0026amp; Refugees      Wilderness and Expedition Medicine  Work-Related Travel        Immunocompromised Travelers   Appendices     Appendix A: Promoting Quality in the Practice of Travel Medicine  Appendix B: Travel Vaccine Summary Table     Appendix C: Migrant Health Resources  Index           Photo credits","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48732539683159,"sku":"9780190628611","price":42.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780190628611.jpg?v=1719997340"},{"product_id":"the-triumph-of-doubt-9780190922665","title":"The Triumph of Doubt","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eOpioids. Concussions. Obesity. Climate change. America is a country of everyday crises -- big, long-spanning problems that persist, mostly unregulated, despite their toll on the country''s health and vitality. And for every case of government inaction on one of these issues, there is a set of familiar, doubtful refrains: The science is unclear. The data is inconclusive. Regulation is unjustified. It''s a slippery slope. Is it?The Triumph of Doubt traces the ascendance of science-for-hire in American life and government, from its origins in the tobacco industry in the 1950s to its current manifestations across government, public policy, and even professional sports. Well-heeled American corporations have long had a financial stake in undermining scientific consensus and manufacturing uncertainty; in The Triumph of Doubt, former Obama and Clinton official David Michaels details how bad science becomes public policy -- and where it''s happening today. Amid fraught conversations of alternative facts and truth decay, The Triumph of Doubt wields its unprecedented access to shine a light on the machinations and scope of manipulated science in American society. It is an urgent, revelatory work, one that promises to reorient conversations around science and the public good for the foreseeable future.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e[Michaels] documents not only a shocking disregard for human welfare on the part of big business, but also a co-ordinated effort to compromise the culture of knowledge itself. * Times Literary Supplement *\u003cbr\u003e...chock full of good examples that were clearly researched (averaging over 30 references per chapter) and supplemented with Michaels' personal experiences. I think any scientist who wants to bridge the realm of research, policy, politics and ethics would benefit from reading this book. * JULIE POLLOCK, Chemistry World *\u003cbr\u003eDavid Michaels opens our eyes to the methods corporations employ that bend the facts of science in order to make a profit. * Chemistry World *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Introduction  2. The Science of Deception  3. The Forever Chemical  4. The NFL's Head Doctors  5. A Spirited Denial  6. The Deal with Diesel  7. On Opioids  8. Deadly Dust  9. Working the Refs  10. Volkswagen's Other Bug  11. The Climate Denial Machine  12. Sickeningly Sweet  13. The Party Line  14. Science for Sale 15. Future in Doubt","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48732549251415,"sku":"9780190922665","price":22.09,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780190922665.jpg?v=1719997379"},{"product_id":"steering-against-superbugs-the-global-governance-of-antimicrobial-resistance-9780192899477","title":"Steering Against Superbugs The Global Governance","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAMR is arguably one of the most severe long-term threats to human, animal, and environmental health. There is momentum for global political action around novel and emerging disease threats and Steering Against Superbugs contributes with original and insightful research to inform ongoing and future debates.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eThis volume collects together key insights from across social sciences on AMR governance. AMR is now the third-leading underlying cause of death globally, which is why a global approach and global governance is necessary. Through a global perspective, the case studies in this volume highlight both successes and challenges of local, regional, and global governance for AMR. As we work together across the world to tackle the 'silent' AMR pandemic, I strongly recommend this book for all in the global and public health and policy sphere to help galvanise action to address the insidious and complex health emergency of AMR. * Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance (AMR) *\u003cbr\u003eSteering Against Superbugs comprehensively unpacks the root social drivers of antimicrobial resistance and masterfully situates these drivers in their cultural, historical and political contexts. Rubin, Baekkeskov, and Munkholm have brought together some of the world's leading thinkers in this field and have pro¬vided us with some of the best ideas yet to tackle this intensifying global health challenge that already kills more than 1.2 million people each year. * Professor Steven J. Hoffman, Director of the Global Strategy Lab and the WHO Collaborating Centre on Global Governance of Antimicrobial Resistance, York University, Canada *\u003cbr\u003eThis exciting volume achieves what many have been waiting for: a compen¬dium of social science approaches to antimicrobial resistance. With a focus on governance, the authors demonstrate the strengths of different disciplines by providing evidence at multiple scales of the ways in which antibiotics, and drug resistance, is-and can be-governed. From clinics, to bednets, to global policy spaces, the book introduces the reader to detailed case studies that enlighten and awaken interest in the multiple dimensions that make up the complex challenge of antimicrobial resistance globally. * Professor Clare Chandler, Anthropology of Antimicrobial Resistance lead and founding Director, AMR Centre, London School of Hygiene \u0026amp; Tropical Medicine. *\u003cbr\u003eMicrobes, humans, One Health, and the interplay between them through AMR. This book introduces the reader to the conceptual issues of AMR, and then steers her through governance challenges, One Health aspects, global awareness, advocacy and regulatory matters. This is essential reading, not just for those working in this critical field but also for policy- makers, healthcare leaders, One Health professionals, and the wider community-providing an armament of knowledge, insight, and perspectives in the fight against AMR. * Professor \u0026amp; Head Sujith J Chandy, Department of Pharmacology \u0026amp; Clinical Pharmacology, Christian Medical College Vellore, India *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1: Steering against Superbugs: Research agenda and four perspectives for global governance Part I: Framing and conceptualizing AMR 2: Pills and Politics - a historical analysis of international antibiotic regulation since 1945 3: Global eradicationism and AMR 4: Conceptualizing AMR as a creeping disaster in terms of pace and space Part II: Coordination and leadership in AMR governance 5: Combatting AMR in the EU - governmental dimensions 6: Contested governance of collective action against AMR in the EU 7: What would it take to move the global AMR agenda forward in the Global South? Part III: AMR Governance from below 8: The individual in global and national AMR governance 9: Governing AMR: a case for considering governance 10: A sociological look beyond the surface of the national action plans against AMR: How state professionals adjust to global governance Part IV: A One Health Perspective on AMR 11: One Health and AMR governance 12: From policy to practice: Challenges and opportunities for cross-sectoral AMR mitigation and response efforts 13: Joint action against AMR with a One Health perspective Part V: Global advocacy and awareness of AMR 14: Policy entrepreneurship and problem brokering in the global governance of AMR 15: Global attention to Antimicrobial Resistance and Climate Change in the era of Social Media 16: The policy context for responses to antimicrobial resistance in India Part VI: Regulatory responses to AMR 17: A case for the global governance of AMR by regulating the pharmaceutical supply chain 18: Sustainable procurement of pharmaceuticals - a tool to combat global antimicrobial resistance 19: International Law and AMR: Learning from 15 years implementing the International Health Regulations","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732615082327,"sku":"9780192899477","price":42.74,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780192899477.jpg?v=1719997661"},{"product_id":"cdc-yellow-book-2024-9780197570944","title":"CDC Yellow Book 2024","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eFor over half a century, the CDC Yellow Book has been a trusted resource, providing international travelers and clinicians with expert guidance for safe and healthy travel abroad. Along with disease-specific prevention and treatment recommendations, this comprehensive reference text provides readers with the background and context needed to understand and address health threats associated with all types of international travel.FEATURED IN THIS EDITION: Precautions for international travelers during the coronavirus disease 2019 (COVID-19) pandemic, including links to updated information on related CDC and US government websites Updates on practicing travel medicine in a virtual environment New standalone vaccine tables for bacterial and viral diseases with links to the relevant Advisory Committee on Immunization Practices and US FDA websites Safe international travel with pets and service animals Advice for obtaining healthcare abroad including guidance on different types of travel insurance Guidelines for self-treating common travel conditions including altitude illness, jet lag, motion sickness, and travelers'' diarrhea Detailed maps showing the distribution of travel-associated infections and diseases, including dengue and meningococcal meningitis Country-specific mosquito avoidance, yellow fever vaccine, and malaria prevention recommendations Food and drink precautions, plus updated water-disinfection techniques Expanded content on safe international travel for specific groups including: LGBTQ+ individuals, highly allergic travelers, travelers with substance use issues, and medical tourists Specialized recommendations for non-leisure travelers, study abroad, work-related travel, and travel to mass gatherings Health insights for 14 popular destinations and itineraries in Africa and the Middle East, the Americas and the Caribbean, and Asia Considerations for newly arrived adoptees, immigrants, and refugees\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eA beloved travel must-have for the intrepid wanderer.\" -Publishers Weekly\u003cbr\u003eA truly excellent and comprehensive resource.\" -Journal of Hospital Infection\u003cbr\u003eThis is a very well-written book that provides a great explanation of the core principles of travel medicine. This [2020] edition includes updated recommendations on some of the vaccines, such as the yellow fever vaccine. An understanding of the concepts in this book serves the needs of clinicians who aim to conquer the outbreaks of infectious diseases associated with travel. (Weighted Numerical Score: 100 - 5 Stars!) * Manasa Velagapudi, Doodys *\u003cbr\u003eThis is the gold-standard in the field of travel medicine due to its enormous scope, expertise, and ease of use. * Kenneth Schaefle, MD, Albert Einstein College of Medicine, Doody's Book Review *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Maps, by topic   CDC Contributors   External Contributors   Acknowledgments   Preface   Dedication       1 Introduction    Disease Patterns in Travelers      ...perspectives: Why Guidelines Differ   Maps \u0026amp; Travel Medicine   Improving the Quality of Travel Medicine through Education \u0026amp; Training       2 Preparing International Travelers    The Pretravel Consultation      ...perspectives: Travelers' Perception of Risk   Vaccination \u0026amp; Immunoprophylaxis-General Principles   Interactions Between Travel Vaccines \u0026amp; Drugs   Yellow Fever Vaccine \u0026amp; Malaria Prevention Information, by Country   Travelers' Diarrhea      ...perspectives: Antibiotics in Travelers' Diarrhea-Balancing Benefit \u0026amp; Risk   Food \u0026amp; Water Precautions   Water Disinfection   Travel Health Kits   Last-Minute Travelers   Mental Health   LGBTQ+ Travelers   Complementary \u0026amp; Integrative Health Approaches to Travel Wellness   Prioritizing Care for Resource-Limited Travelers   Telemedicine    ...perspectives: Risk Management Issues in Travel Medicine       3 Travelers with Additional Considerations    Immunocompromised Travelers   Travelers with Disabilities   Travelers with Chronic Illnesses   Highly Allergic Travelers   Substance Use \u0026amp; Substance Use Disorders       4 Environmental Hazards \u0026amp; Risks    Sun Exposure   Extremes of Temperature   Air Quality \u0026amp; Ionizing Radiation   Scuba Diving: Decompression Illness \u0026amp; Other Dive-Related Injuries   High Elevation Travel \u0026amp; Altitude Illness   Mosquitoes, Ticks \u0026amp; Other Arthropods   Zoonotic Exposures: Bites, Stings, Scratches \u0026amp; Other Hazards   Zoonoses-The One Health Approach   Bringing Animals \u0026amp; Animal Products into the United States   Food Poisoning from Marine Toxins   Safety \u0026amp; Security Overseas   Injury \u0026amp; Trauma   Death During Travel     5 Travel-Associated Infections \u0026amp; Diseases    BACTERIAL Vaccine-Preventable Diseases: Bacterial   Anthrax   Bartonella Infections   Brucellosis   Campylobacteriosis   Cholera   Diphtheria   Escherichia coli, Diarrheagenic   Helicobacter pylori   Legionnaires' Disease \u0026amp; Pontiac Fever   Leptospirosis   Lyme Disease   Melioidosis   Meningococcal Disease   Pertussis \/ Whooping Cough   Plague   Pneumococcal Disease   Q Fever   Rickettsial Diseases   Salmonellosis, Nontyphoidal   Shigellosis   Tetanus   Tuberculosis      ...perspectives: Testing Travelers for Mycobacterium tuberculosis Infection   Typhoid \u0026amp; Paratyphoid Fever   Yersiniosis     VIRAL  Vaccine-Preventable Diseases: Viral   B Virus   Chikungunya   COVID-19   Dengue   Hand, Foot \u0026amp; Mouth Disease   Henipavirus Infections   Hepatitis A   Hepatitis B   Hepatitis C   Hepatitis E   Human Immunodeficiency Virus \/ HIV   Influenza   Japanese Encephalitis   Middle East Respiratory Syndrome \/ MERS   Mumps   Norovirus  Poliomyelitis   Rabies      ...perspectives: Rabies Immunization   Rubella   Rubeola \/ Measles   Smallpox \u0026amp; Other Orthopoxvirus-Associated Infections   Tick-Borne Encephalitis   Varicella \/ Chickenpox   Viral Hemorrhagic Fevers   Yellow Fever   Zika     PARASITIC  Amebiasis   Angiostrongyliasis   Cryptosporidiosis   Cutaneous Larva Migrans   Cyclosporiasis   Cysticercosis   Echinococcosis   Enterobiasis \/ Pinworm   Filariasis, Lymphatic   Flukes, Liver  Flukes, Lung   Giardiasis   Helminths, Soil-Transmitted   Leishmaniasis, Cutaneous   Leishmaniasis, Visceral   Malaria   Onchocerciasis \/ River Blindness   Sarcocystosis   Scabies   Schistosomiasis   Strongyloidiasis   Taeniasis   Toxoplasmosis   Trypanosomiasis, African   Trypanosomiasis, American \/ Chagas Disease     FUNGAL  Coccidioidomycosis \/ Valley Fever   Histoplasmosis       6 Health Care Abroad    Travel Insurance, Travel Health Insurance \u0026amp; Medical Evacuation Insurance   Obtaining Health Care Abroad      ...perspectives: Avoiding Poorly Regulated Medicines \u0026amp; Medical Products during Travel   Medical Tourism       7 Family Travel    Pregnant Travelers   Travel \u0026amp; Breastfeeding   Traveling Safely with Infants \u0026amp; Children   Vaccine Recommendations for Infants \u0026amp; Children   International Adoption   Traveling with Pets \u0026amp; Service Animals       8 Travel by Air, Land \u0026amp; Sea    Air Travel      ...perspectives: Responding to Medical Emergencies when Flying   Deep Vein Thrombosis \u0026amp; Pulmonary Embolism   Jet Lag   Road \u0026amp; Traffic Safety   Cruise Ship Travel   Motion Sickness   Airplanes \u0026amp; Cruise Ships: Illness \u0026amp; Death Reporting \u0026amp; Public Health Interventions       9 Travel for Work \u0026amp; Other Reasons    The International Business Traveler   Advice for Aircrew      ...perspectives: People Who Fly for a Living-Health Myths \u0026amp; Realities   Health Care Workers, Including Public Health Researchers \u0026amp; Medical Laboratorians   Humanitarian Aid Workers   United States Military Deployments   Long-Term Travelers \u0026amp; Expatriates   Study Abroad \u0026amp; Other International Student Travel   Visiting Friends \u0026amp; Relatives: VFR Travel   Mass Gatherings   Adventure Travel   Sex \u0026amp; Travel       10 Popular Itineraries    The Rationale for Popular Itineraries     AFRICA \u0026amp; THE MIDDLE EAST  African Safaris   Saudi Arabia: Hajj \u0026amp; Umrah Pilgrimages   South Africa  Tanzania \u0026amp; Zanzibar     THE AMERICAS \u0026amp; THE CARIBBEAN   Brazil   Dominican Republic   Haiti   Mexico   Peru     ASIA  Burma (Myanmar)   China   India   Nepal   Thailand       11 Posttravel Evaluation    General Approach to the Returned Traveler   Rapid Diagnostic Tests for Infectious Diseases      ...perspectives: Screening Asymptomatic Returned Travelers   Fever in the Returned Traveler   Antimicrobial Resistance   Respiratory Infections   Persistent Diarrhea in Returned Travelers   Dermatological Conditions      ...perspectives: Delusional Parasitosis   Sexually Transmitted Infections   Newly Arrived Immigrants, Refugees \u0026amp; Other Migrants","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48732652372311,"sku":"9780197570944","price":41.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780197570944.jpg?v=1719997807"},{"product_id":"the-triumph-of-doubt-dark-money-and-the-science-of-deception-9780197675311","title":"The Triumph of Doubt Dark Money and the Science","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWell-heeled American corporations have long had a financial stake in undermining scientific consensus and manufacturing uncertainty. In The Triumph of Doubt, former Obama and Clinton official David Michaels details how corrupt science becomes public policy -- and where it''s happening today. Opioids. Concussions. Obesity. Climate Change.America is a country of everyday crises -- big, long-spanning problems that persist despite their toll on the country''s health. And for every case of government inaction on one of these issues, there is a set of familiar, doubtful refrains: The science is unclear. The data are inconclusive. Regulation is unjustified. It''s a slippery slope.Is it?The Triumph of Doubt traces the ascendance of science-for-hire in American life and government, from its origins in the tobacco industry in the 1950s to its current manifestations across government, public policy, and even professional sports. Amid fraught conversations of alternative facts and truth decay, The Triumph of Doubt wields its unprecedented access to shine a light on the machinations and scope of manipulated science in American society. It is an urgent, revelatory work, one that promises to reorient conversations around science and the public good for the foreseeable future.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e[Michaels] documents not only a shocking disregard for human welfare on the part of big business, but also a co-ordinated effort to compromise the culture of knowledge itself. * Times Literary Supplement *\u003cbr\u003e...chock full of good examples that were clearly researched (averaging over 30 references per chapter) and supplemented with Michaels' personal experiences. I think any scientist who wants to bridge the realm of research, policy, politics and ethics would benefit from reading this book. * JULIE POLLOCK, Chemistry World *\u003cbr\u003eIt is so refreshing to read David Michaels' The Triumph of Doubt. He has the facts researched, vetted and thoroughly cited, and is not afraid to lay blame, call people liars and companies frauds. * San Francisco Review of Books *\u003cbr\u003eDavid Michaels opens our eyes to the methods corporations employ that bend the facts of science in order to make a profit. * Chemistry World *\u003cbr\u003eDavid Michaels is that rare combination: the fearless expert. He not only knows where the bodies are buried, he knows who buried them. The Triumph of Doubt and its predecessor, Doubt Is Their Product, are timely, readable, and essential guides for anyone seeking to understand how the corruption of science is damaging the health of everyone from football players and factory workers to soda drinkers and truck drivers-in short, anyone with a pulse. * Dan Fagin, author of the Pulitzer Prize-winning Toms River *\u003cbr\u003eDavid Michaels lays bare the dark money and the corporate science racket that kept the lethalities of tobacco, asbestos, lead, silica, pesticides, and scores of other life- and health-destroying products on the market and in the workplace, escaping the reach of the law. He names names of people and companies fronted by their so-called 'product defense' business and its corporate attorney enablers; delays, obfuscation, falsehood, and retaliation against ethical whistleblowers are the coins of their insidious realms. This book is written to get you angry enough to want to learn how to defend yourselves, your communities, and our vulnerable planet. Let it grip you toward detection and defiance.\" * Ralph Nader *\u003cbr\u003eAs a society, it's vital we properly debate issues using data and research. The Triumph of Doubt, David Michaels's wonderfully deep dive into the well-funded war on scientific consensus and certainty, makes the stakes clear: our planet. Read this.\" * Adam Savage, Mythbusters *\u003cbr\u003eNo one has done more to expose the deep corruption in American safety regulation that harms us all-and especially our kids. After spending seven years as America's chief safety regulator, David Michaels offers a beautifully crafted argument for how much more we need to do. Required-if frightening-reading for anyone who cares about a clean and safe environment for America and the world.\" * Lawrence Lessig, author of Fidelity and Constraint *\u003cbr\u003eA page-turner-one you'll wish was fiction. From hired guns to dark money, The Triumph of Doubt unravels corporations' playbook for deceiving the public through misinformation.^ * Mona Hanna-Attisha, author of What the Eyes Don't See   *\u003cbr\u003eThe Triumph of Doubt is an industry-by-industry account of how corporations manipulate science and scientists to promote profits, not public health. Nothing less than democracy is at stake here, and we all should be responding right away to David Michaels' call for action. * Marion Nestle, author of Unsavory Truth   *\u003cbr\u003eIt takes real courage to speak out against entrenched corporate interests and big industry. I saw that courage firsthand when I worked alongside Dr. Michaels in the Obama administration to protect workers at construction sites from cancer-causing silica dust. The Triumph of Doubt doesn't just tell the story of how we overcame the falsehoods of industry-funded studies, it shines a disinfecting light on the ways corporations obscure the truth and downplay risk to pump up their bottom line. This is a must-read.\" * Tom Perez, former U.S. Labor Secretary   *\u003cbr\u003eA compelling and necessary work for anyone interested in the truth and those who seek to bury it. Michaels details the methods used by those in power to hide the truth-and the moral bankruptcy at work when they do so.\" * Demaurice Smith, National Football League Players Association Executive Director *\u003cbr\u003eAs a third-generation coal miner from a family who has suffered the deadly consequences of Black Lung, I know firsthand that worker safety should never be politicized. David Michaels's book is a must-read for business, labor and the scientific community.\" * Richard Trumka, AFL-CIO President   *\u003cbr\u003eDavid Michaels provides well-written evidence in his book about how corporations that produce dangerous products-tobacco, big oil, chemicals, pharmaceuticals-use 'product defense' science to sow doubt about the hazards hidden in their products to consumers. His evidence highlights the important role unbiased government scientists play in protecting the public health of Americans and our environment from exposure to toxic materials and from corporate deceit. * Senator Tom Udall   *\u003cbr\u003eFrom the pharmaceutical industry's role in the opioid crisis to the Koch brothers' climate denial apparatus, Michaels examines big industry's jarring history of manufacturing false scientific doubt in the name of profit. This is an important book that will serve as a tool in exposing corporate deceit. * Senator Sheldon Whitehouse   *\u003cbr\u003eWhether it's the tobacco industry, the pharmaceutical industry, or the fossil fuel industry, vested interests have repeatedly sought to attack and discredit scientific findings that have revealed the public endangerment by their products. David Michaels should know-he's been fighting the good fight for more than a decade to expose the bad actors and bring them to justice. Read this book to learn what we're up against and how to fight back. * Michael E. Mann, author of The Madhouse Effect   *\u003cbr\u003ePoisoning the well of public debate is the ultimate act of cynicism. As David Michaels makes breathtakingly clear, one industry after another has lied and manipulated in order to make more money, and the rest of us have borne the terrible costs.\" * Bill McKibben, author of Falter   *\u003cbr\u003eWhile the truth can be inconvenient, corporations and government leaders cannot continue to manufacture alternative narratives that place their interests and profits above our humanity; this culture, if left unchallenged, will result in our doom. The Triumph of Doubt reminds us that there can only be one truth.\" * Bennet Omalu, author of Truth Doesn't Have a Side   *\u003cbr\u003eFew people have done more to document disinformation about science than David Michaels. His new book is an important addition to the growing literature on doubt, disinformation, and deception. * Naomi Oreskes, author of Merchants of Doubt   *\u003cbr\u003eIn the NFL, team doctors answer to the organization; players joke that it's like Dracula running the blood bank. It's a microcosm of what David Michaels brilliantly illuminates in The Triumph of Doubt: When corporations manipulate science and launch marketing campaigns to sow doubt, they ensure human suffering. Michaels's work is vital reading for everyone to understand these industry tactics. * Chris Borland, former NFL player   *\u003cbr\u003eScientist, public servant, and passionate advocate for health and safety, Michaels has written an absorbing sequel to his path-breaking work on manufactured doubt. He documents how powerful corporations have turned 'product defense' into a new political strategy, using dark money to pummel good science and keep dangerous products on the market. A must-read in the fight to restore public trust in regulatory science.\" * Sheila Jasanoff, Harvard Kennedy School *\u003cbr\u003eDriven by scientific interest, The Triumph of Doubt is a measured but passionate argument for protecting the public from harmful substances via federal oversight.\" * Foreword Reviews *\u003cbr\u003e[An] excoriating account of the corporate denial industry... It is a brave and important book, raising the alarm about the systemic corruption of science. * Felicity Lawrence, Nature     *\u003cbr\u003eA tour de force that examines how frequently, and easily, science has been manipulated to discredit expertise and accountability on issues ranging from obesity and concussions to opioids and climate change. * Science *\u003cbr\u003eDavid Michaels shows that Big Tobacco's well-known denial tactics have not faded into history, but instead have become an integral part of corporate America's standard business practices. * Undark Magazine *\u003cbr\u003eA no-holds barred page-turner. In a series of case studies, it names names and describes how powerful players prioritize a requirement of absolute proof over precaution when it comes to exposures' impacts on human health. * Union of Concerned Scientists *\u003cbr\u003e[Michaels'] book is a timely, must read indictment of product defense 'science.'\" * Pittsburgh Post-Gazette   *\u003cbr\u003eDavid Michaels opens our eyes to the methods corporations employ that bend the facts of science in order to make a profit. * Chemistry World *\u003cbr\u003e[A] close look at how powerful corporations fund junk science and misinformation campaigns in order to obscure evidence and undercut regulatory efforts.\" * Vox  *\u003cbr\u003eThe Triumph of Doubt is a carefully researched review of corporate-funded strategies and practices that undermine public health policies of all kinds. And while it sometimes makes one's blood boil, it is still a gripping read. * New Solutions *\u003cbr\u003e[An] excoriating account of the corporate denial industry.... It is a brave and important book, raising the alarm about the systemic corruption of science. * Nature  *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Introduction  2. The Science of Deception  3. The Forever Chemical  4. The NFL's Head Doctors  5. A Spirited Denial  6. The Deal with Diesel  7. On Opioids  8. Deadly Dust  9. Working the Refs  10. Volkswagen's Other Bug  11. The Climate Denial Machine  12. Sickeningly Sweet  13. The Party Line  14. Science for Sale 15. Future in Doubt","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48732673016151,"sku":"9780197675311","price":20.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780197675311.jpg?v=1719997893"},{"product_id":"psychosis-global-perspectives-9780198735588","title":"Psychosis Global Perspectives","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003ePsychotic disorders are a major public health challenge. Psychoses are associated with significant individual, familial, and societal costs. Yet, our understanding of these conditions is limited because the overwhelming majority of research is conducted in a small number of countries in North America, Europe, and Australasia, which together comprise only around 16% of the world''s population. There are consequently substantial gaps in our knowledge of psychoses, and the need for a global perspective is obvious.Psychosis: Global Perspectives comprises two parts: In the first half of the book, the authors review the current evidence base on psychoses around the world by theme, from epidemiology to human rights, highlighting commonalities and differences between settings and illustrating the gaps in our knowledge. The second half of the book synthesises existing research from nine countries in the Global South, providing detailed accounts of ongoing research programmes, local treatment sy\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart I Psychosis by Topic 1: Ozden Merve Mollaahmetoglu and James B. Kirkbride: Psychosis across place: The madding crowdDL urban living and psychosis 2: Els van der Ven: Psychosis across persons 1: Minority ethnic groups and migration 3: Charlotte Gayer-Anderson, Stephanie Beards, and Ulrich Reininghaus: Psychosis across persons 2: Poverty, trauma, and sociodevelopment 4: Giulia Segre, Conrad Iyegbe, Sarah Tosato, Geraldo Busatto, and Paola Dazzan: Psychosis across persons 3: Genes, biology, and neurodevelopment 5: Jonathan K. Burns: Psychosis across persons 4: Course and outcome 6: Alex Cohen: Mortality and psychosis 7: Neely Anne Laurenzo Myers: Psychosis, phenomenology, and culture: Welcoming the 'black box' 8: Ashok Malla and Srividya N. Iyer: Services and systems of care for psychotic disorders: A global perspective 9: Ursula M. Read and Erminia Colucci: Human rights and psychosis Part II Psychosis by Place 10: Cristina Marta Del-Ben, Rosana Shuhama, and Paulo Rossi Menezes: Ribeirao Preto, Brazil: Incidence and risks 11: Gerard Hutchinson: Trinidad and Tobago 12: Oye Gureje, Akin Ojagbemi, and Oluyomi Esan: Nigeria 13: Charlotte Hanlon, Alex Cohen, and Atalay Alem: Ethiopia 14: Jonathan K. Burns and Bonginkosi Chiliza: KwaZulu-Natal, South Africa 15: Dzmitry Krupchanka, Petr Winkler,  Arunas Germanavicius, Jan Pfeiffer, Cyril Höschl, Oksana Plevachuk, and Orest Suvalo: Central and Eastern Europe 16: Rangaswamy Thara, Sujit John, Ramachandran Padmavati, Greeshma Mohan, and Vijaya Raghavan: Chennai, India 17: Christy Lai Ming Hui, Wing Chung Chang, Sherry Kit Wa Chan, Edwin Ho Ming Lee, and Eric Yu Hai Chen: Hong Kong 18: Shuiyuan Xiao and Lu Niu: Psychoses and mental health services in mainland China 19: Tessa Roberts, Alex Cohen, and Craig Morgan: Future directions","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732773417303,"sku":"9780198735588","price":55.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780198735588.jpg?v=1719998336"},{"product_id":"pandemics-9780199340071","title":"Pandemics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe 2014 Ebola epidemic demonstrated the power of pandemics and their ability not only to destroy lives locally but also to capture the imagination and terrify the world. Christian W. McMillen provides a concise yet comprehensive account of pandemics throughout human history, illustrating how pandemic disease has shaped history and, at the same time, social behavior has influenced pandemic disease. Extremely interesting from a medical standpoint, the study of pandemics also provides unexpected, broader insights into culture and politics.This Very Short Introduction describes history''s major pandemics - plague, tuberculosis, malaria, smallpox, cholera, influenza, and HIV\/AIDS - highlighting how each disease''s biological characteristics affected its pandemic development. McMillen discusses state responses to pandemics, such as quarantine, isolation, travel restrictions, and other forms of social control, and pays special attention to the rise of public health and the explosion of medical research in the wake of pandemics, especially as the germ theory of disease emerged in the late nineteenth and early twentieth centuries. Today, medicine is able to control all of these diseases, yet some of them are still devastating in much of the developing world. By assessing the relationship between poverty and disease and the geography of epidemics, McMillen offers an outspoken and thought-provoking point of view on the necessity for global governments to learn from past experiences and proactively cooperate to prevent any future epidemic.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eIntroduction Chapter 1: Plague  Chapter 2: Smallpox  Chapter 3: Malaria Chapter 4: Cholera  Chapter 5: Tuberculosis  Chapter 6: Influenza Chapter 7: HIV\/AIDS  References Further Reading Index","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48732841410903,"sku":"9780199340071","price":9.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780199340071.jpg?v=1719998627"},{"product_id":"epidemiology-9780199543335","title":"Epidemiology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWhat is epidemiology? What are the causes of a new disease? How can pandemics be prevented? Epidemiology is the study of the changing patterns of disease and its main aim is to improve the health of populations. It''s a vital field, central to the health of society, to the identification of causes of disease, and to their management and prevention. Epidemiology has had an impact on many areas of medicine; from discovering the relationship between tobacco smoking and lung cancer, to the origin and spread of new epidemics. However, it is often poorly understood, largely due to misrepresentations in the media.In this Very Short Introduction Rodolfo Saracci dispels some of the myths surrounding the study of epidemiology. He provides a general explanation of the principles behind clinical trials, and explains the nature of basic statistics concerning disease. He also looks at the ethical and political issues related to obtaining and using information concerning patients, and trials involving placebos.ABOUT THE SERIES: The Very Short Introductions series from Oxford University Press contains hundreds of titles in almost every subject area. These pocket-sized books are the perfect way to get ahead in a new subject quickly. Our expert authors combine facts, analysis, perspective, new ideas, and enthusiasm to make interesting and challenging topics highly readable.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. What is epidemiology? ; 2. Measuring health and disease ; 3. Searching for the causes of diseases ; 4. Establishing the causes of a disease ; 5. Testing how to control a disease ; 6. Following-up people's health ; 7. Enquiring back into people's lives ; 8. Mapping health and disease ; 9. From epidemiology to medicine, prevention, and public health ; 10. Epidemiology between ethics and politics","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732856615255,"sku":"9780199543335","price":9.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780199543335.jpg?v=1719998691"},{"product_id":"keep-calm-and-trust-the-science-9780717191819","title":"Keep Calm and Trust the Science","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eTake a front row seat with Professor Luke O'Neill on a high-octane year. Luke has become one of the most well-known and trusted voices of Ireland's COVID-19 pandemic. A world-renowned immunologist, he was thrust into the spotlight as we struggled to make sense of a crisis that saw the country grind to a halt. In these compelling diaries, Luke reveals what life was like behind the scenes as he endeavoured to keep calm and trust that the science would save us.\u003c\/p\u003e\u003cp\u003eSet against a national backdrop of banana-bread baking, TikTok dancing and outdoor bingo, as well as the devastation to life and livelihood suffered by many, Luke's lockdown diaries reveal the highs and lows of work at the cutting edge of science in his Trinity College lab along with how he coped personally with the pressures of public life.\u003c\/p\u003e\u003cp\u003eShot through with the natural positivity and humour that have made Luke a home-grown hero,\u003cem\u003e Keep Calm and Trust the Science \u003c\/em\u003eis an unputdownable account of one of the most\u003c\/p\u003e","brand":"Gill","offers":[{"title":"Default Title","offer_id":48736127123799,"sku":"9780717191819","price":15.29,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780717191819.jpg?v=1723810517"},{"product_id":"practical-computing-for-biologists-9780878933914","title":"Practical Computing for Biologists","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003ePublished by Sinauer Associates, an imprint of Oxford University Press.  Increasingly, scientists find themselves facing exponentially larger data sets and analyses without suitable tools to deal with them. Many biologists end up using spreadsheet programs for most of their data-processing tasks and spend hours clicking around or copying and pasting, and then repeating the process for other data files.Practical Computing for Biologists shows you how to use many freely available computing tools to work more powerfully and effectively. The book was born out of the authors'' own experience in developing tools for their research and helping other biologists with their computational problems. Although many of the techniques are relevant to molecular bioinformatics, the motivation for the book is much broader, focusing on topics and techniques that are applicable to a range of scientific endeavors. Twenty-two chapters organized into six parts address these topics (and more; see Contents): * \u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003ePractical Computing for Biologists is a clear guide to methods that unlock the power of the personal computer. Although the breadth of subjects covered is certainly an asset of this volume, what really makes the book stand out is how well the authors clearly describe each technique and its applicability to biological sciences. It is a great launching point for any necessary further investigation of computational techniques. * Matthew Aiello-Lammens, The Quarterly Review of Biology *\u003cbr\u003eThe book covers a wide range of subjects that truly justifies the title of 'practical computing.' In addition to the usual programming-related topics, it also includes a thorough introduction to the programming environment, approaches to combining different programs together, a description of the basic text manipulation tools such as regular expressions, and even an introduction to dealing with digital art and images. As such the book is great value for the money, being at least three books in one. * Olga G. Troyanskaya, Cell *\u003cbr\u003eMy copy of Practical Computing for Biologists arrived last week, and I've been very impressed. It is a well-written, well-paced guide to basic computing skills for scientists and engineers of all stripes (not just biologists). It is beautifully produced: full-color printing and great graphical design make this book a joy to read. If I ever do turn Software Carpentry into a book, I might skip the topics PCB covers and just tell people to go and buy it. * Greg Wilson, software-carpentry.org *\u003cbr\u003eWhen considering my research and use of time, this book has been the most important book I've read in the last year, and perhaps the last decade. Striking a perfect balance by guiding you through tutorials and nudging your own self-exploration, the book has just enough guided direction to not annoy or overwhelm. It has helped (and is still helping) me to do what I was doing before, but more efficiently. * Cyme \u0026amp; Cystidium *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eBefore You Begin.- PART I: TEXT FILES.- Getting Set Up.- Regular Expressions: Powerful Search \u0026amp; Replace.- Exploring the Flexibility of Regular Expressions.- PART II: THE SHELL.- Command-line Operations: The Shell.- Handling Text in the Shell.- Scripting with the Shell.- PART III: PROGRAMMING.- Components of Programming.- Beginning Python Programming.- Decisions and Loops.- Reading and Writing Files.- Merging Files.- Modules and Libraries.- Debugging Strategies.- PART IV: COMBINING METHODS.- Selecting and Combining Tools.- Relational Databases.- Advanced Shell and Pipelines.- PART V: GRAPHICS.- Graphical Concepts.- Working with Vector Art.- Working with Pixel Images.- PART VI: ADVANCED TOPICS.- Working on Remote Computers.- Installing Software.- Electronics: Interacting with the Physical World.- APPENDICES.- Working with other Operating Systems.- Regular Expression Search Terms.- Shell Commands.- Python Quick Reference.- Template Programs.- Binary, Hex, and ASCII.- SQL Commands.- Index.\u003cbr\u003e","brand":"Oxford University Press Inc","offers":[{"title":"Default Title","offer_id":48737792131415,"sku":"9780878933914","price":109.24,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780878933914.jpg?v=1723811467"},{"product_id":"marijuana-and-madness-9781009305433","title":"Marijuana and Madness","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eA fully updated third edition covering the current research and clinical aspects on the interactions between cannabis and mental illness. Extensively expanded to include new chapters on prenatal cannabis exposure, addiction genetics, cannabis withdrawal, and cannabis and sleep. Essential reading for all members of the mental health team.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'The 3rd edition of this authoritative book is remarkably up-to-date and reflects well the current state of play in both the neuroscience and clinical approaches at the interface between mental health and cannabis. The updated textbook covers the essentials of cannabis and health and, most importantly, policy in an integrated and impressively comprehensive manner. Each chapter includes both important recent publications as well as seminal papers, particularly important given the evolution of information on cannabis and contemporary considerations for public health. The chapters, authored by world renowned experts, are well written and I particularly liked the explicit tables\/ boxes. My distinguished colleagues and friends Drs D'Souza, Castle, and Murray are to be congratulated for providing us with this outstanding, authoritative, and remarkably contemporary book on mental health and cannabis.' Peter F. Buckley, M.D., Chancellor, The University of Tennessee Health Science Center, Memphis, Tennessee\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart I. Pharmacology of Cannabis and the Endocannabinoid System: 1. How cannabis works in the brain Ken Mackie; 2. The function of the endocannabinoid system Nathan D. Winters and Sachin Patel; 3. Synthetic cannabinoids Liana Fattore and Matteo Marti; Part II. The Changing Face of Cannabis: 4. The epidemiology of cannabis use and cannabis use disorder Deborah Hasin; 5. Is cannabis becoming more potent? Tom P. Freeman and Sam Craft; 6. Policy implications of the evidence on cannabis use and psychosis Wayne Hall and Louisa Degenhardt; Part III. Cannabis and the Brain: 7. The impact of pubertal exposure to cannabis on the brain: a focus on animal studies Erica Zemberletti and Tiziana Rubino; 8. The impact of cannabis exposure on the adolescent brain: humans studies and translational insights Jacqueline-Marie Ferland, Alexandra Chisholm and Yasmin L. Hurd; 9. Cannabis and cognition: an update on short- and long-term effects Lisa-Marie Greenwood, Valentina Lorenzetti and Nadia Solowij; 10. Is there a cannabis-associated psychosis subtype? Lessons from biological typing in the b-snip project, and implications for treatment Godfrey Pearlson and Matcheri S. Keshavan; Part IV. Cannabis, Anxiety and Mood: 11. Cannabis and anxiety Grace Lethbridge, Beth Patterson and Michael Van Ameringen; 12. Cannabis consumption and risk of depression and suicidal behaviour Gabriella Gobbi; 13. Cannabis and bipolar disorder Jairo Pinto and Mauren Leticia Ziak; Part V. Cannabis and Psychosis: 14. Cannabis and psychosis proneness Rajiv Radhakrishnan, Shubham Kamal, Sinan Guloksuz and Jim van Os; 15. Which cannabis users develop psychosis? Edoardo Spinazzola, Marta Di Forti and Robin M. Murray; 16. Cannabis causes positive, negative, cognitive symptoms and produces impairments in electrophysiological indices of information processing Ashley Martin-Schnakenberg, Mohini Ranganathan and D. Cyril D'Souza; Part VI. Cannabinoids and Schizophrenia: Aetiopathology and Treatment Implications: 17. Does cannabis cause schizophrenia? Emmet Power, Colm Healy, Robin M. Murray and Mary Cannon; 18. Postmortem studies of the brain cannabinoid system in schizophrenia Suresh Sundram, Brian Dean and David Copolov; 19. The endocannabinoid system in schizophrenia Paul Morrison; 20. Cannabidiol as a potential antipsychotic F. Markus Leweke and Cathrin Rohleder; 21. Genetic explanations for the association between cannabis and schizophrenia Sarah M. Colbert and Emma Johnson; Part VII. Cannabis and its Impact on Schizophrenia: 22. Acute effects of cannabinoids in people with a psychotic illness Suhas Ganesh, Cécile Henquet, R. Andrew Sewell, Rebecca Kuepper, Mohini Ranganathan and Deepak Cyril D'Souza; 23. Cannabis and the long-term course of schizophrenia Tabea SchoeleR; 24. Treating cannabis use in schizophrenia and other psychotic disorders Alexandria S. Coles, Ashley E Kivlichian, David J. Castle and Tony P. George; Part VIII. Special Topics: 25. Prenatal cannabis exposure: associations with development and behavior Sarah E. Paul, Cynthia E. Rogers and Ryan Bogdan; 26. Cannabis use and violence Giulia Trotta, Paolo Marino, Victoria Rodriguez, Robin M. Murray and Evangelos Vassos; 27. Cannabis withdrawal Jane Metrik and Kayleigh McCarty; 28. Cannabis and addiction Valerie Curran, Will Lawn and Tom P. Freeman; 29. Tobacco use among cannabis users: insights into co-use and why it matters for people with psychosis Rachel A. Rabin, Erin A. McClure and Tony P. George; 30. Cannabis addiction genetics Suhas Ganesh and Arpana Agrawal; 31. Snoozing on pot: cannabis and sleep Patrick D. Skosnik and Toral S. Surti; 32. Cannabinoids as medicines: what the evidence says and what it does not say Marco De Toffol, Elena Dragioti, Andre Ferrer Carvalho, and Marco Solmi.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738022621527,"sku":"9781009305433","price":47.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781009305433.jpg?v=1723811685"},{"product_id":"economics-of-healthcare-9781009258456","title":"Economics of Healthcare","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten in an informal and easy-going style suitable for a wide range of readers, this textbook uses real-world examples to teach the institutional details of healthcare and health insurance and explain the economics that underpin the behaviour of key players in these markets. A complete one-stop-shop for learning about the economics of healthcare.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'This is the book health economics instructors and students have been waiting for! The real-world examples immediately draw in readers and provide a foundation for looking at important issues in health care from an economic perspective. Dr. Friedson's approach to examining complex topics is both intuitive and hilarious.' Elizabeth Munnich, University of Louisville\u003cbr\u003e'A captivating tour of the economic foundations of modern healthcare. With practical examples and delightful humor, this book effortlessly breaks down complex concepts, making health economics accessible to diverse readers. A must-have resource for students seeking a comprehensive grasp of healthcare markets and the challenges they entail.' Sarah Miller, University of Michigan\u003cbr\u003e'This is a book on the economics of healthcare that is well organized, comprehensive in its coverage, and actually fun to read! It is well suited for a diverse audience, including undergraduate and graduate students from different degree programs, practitioners, and policy makers.' James H. Marton, Georgia State University\u003cbr\u003e'The hallmark of this book is its dedication to practicality. Demanding no prerequisite economics background, Friedson's 'Health Economics' is ideal for students and professionals in public health and healthcare management. Rich with insights into the economics of the healthcare industry, it occupies a unique space in the health economics literature.' Natallia Grey, Iowa State University\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface; Acknowledgments; Part I. Patients: 1. How Economists View Human Behavior; 2. Where Does Health Come From?; 3. Demand for Medical Care; 4. Health Insurance and Demand for Medical Care; 5. Evaluating Evidence; Part II. Providers: 6. Provider Firms; 7. The Medical Labor Force; 8. Providers and Incentives; 9. Hospitals; Part III. Health Insurers: 10. Health Insurance as a Product; 11. Adverse Selection; 12. Prices; 13. Managed Care; 14. Public Insurance; Part IV. The Sector at Large; 15. Pharmaceuticals; 16. Externalities; 17. Medical Malpractice; 18. Inequality; 19. International Comparisons.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738023014743,"sku":"9781009258456","price":94.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781009258456.jpg?v=1723811687"},{"product_id":"economics-of-healthcare-9781009258432","title":"Economics of Healthcare","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten in an informal and easy-going style suitable for a wide range of readers, this textbook uses real-world examples to teach the institutional details of healthcare and health insurance and explain the economics that underpin the behaviour of key players in these markets. A complete one-stop-shop for learning about the economics of healthcare.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'This is the book health economics instructors and students have been waiting for! The real-world examples immediately draw in readers and provide a foundation for looking at important issues in health care from an economic perspective. Dr. Friedson's approach to examining complex topics is both intuitive and hilarious.' Elizabeth Munnich, University of Louisville\u003cbr\u003e'A captivating tour of the economic foundations of modern healthcare. With practical examples and delightful humor, this book effortlessly breaks down complex concepts, making health economics accessible to diverse readers. A must-have resource for students seeking a comprehensive grasp of healthcare markets and the challenges they entail.' Sarah Miller, University of Michigan\u003cbr\u003e'This is a book on the economics of healthcare that is well organized, comprehensive in its coverage, and actually fun to read! It is well suited for a diverse audience, including undergraduate and graduate students from different degree programs, practitioners, and policy makers.' James H. Marton, Georgia State University\u003cbr\u003e'The hallmark of this book is its dedication to practicality. Demanding no prerequisite economics background, Friedson's 'Health Economics' is ideal for students and professionals in public health and healthcare management. Rich with insights into the economics of the healthcare industry, it occupies a unique space in the health economics literature.' Natallia Grey, Iowa State University\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface; Acknowledgments; Part I. Patients: 1. How Economists View Human Behavior; 2. Where Does Health Come From?; 3. Demand for Medical Care; 4. Health Insurance and Demand for Medical Care; 5. Evaluating Evidence; Part II. Providers: 6. Provider Firms; 7. The Medical Labor Force; 8. Providers and Incentives; 9. Hospitals; Part III. Health Insurers: 10. Health Insurance as a Product; 11. Adverse Selection; 12. Prices; 13. Managed Care; 14. Public Insurance; Part IV. The Sector at Large; 15. Pharmaceuticals; 16. Externalities; 17. Medical Malpractice; 18. Inequality; 19. International Comparisons.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738030190935,"sku":"9781009258432","price":34.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"making-sense-of-medical-statistics-9781108978156","title":"Making Sense of Medical Statistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eDo you want to know what a parametric test is and when not to perform one? Do you get confused between odds ratios and relative risks? Want to understand the difference between sensitivity and specificity? Would like to find out what the fuss is about Bayes'' theorem? Then this book is for you! Physicians need to understand the principles behind medical statistics. They don''t need to learn the formula. The software knows it already! This book explains the fundamental concepts of medical statistics so that the learner will become confident in performing the most commonly used statistical tests. Each chapter is rich in anecdotes, illustrations, questions, and answers. Not enough? There is more material online with links to free statistical software, webpages, multimedia content, a practice dataset to get hands-on with data analysis, and a Single Best Answer questionnaire for the exam.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'An accessible book by a practising doctor, aimed at other doctors, which explains key statistical concepts in words and pictures. An excellent foundation for those seeking to understand the numbers in medical journal articles and quantitative reports.' Professor Trish Greenhalgh, University of Oxford, UK\u003cbr\u003e'Statistics forms the starting point for evidence based medicine, though most medics would argue that their own statistical awareness is still near the starting point! This book eases you into the awesome, exciting, exhilarating world of statistics, and makes you understand just how cool it really is. It will unleash your inner statistician that no-one knew existed - especially you!' Professor Dan Perry, Children's Orthopaedic Surgeon and Fellow of Wolfson College, University of Oxford, UK\u003cbr\u003e'The book provides a light-hearted introduction to the basic concepts in medical statistics. A couple of hundred pages long with short chapters, the book delivers with clear focus the key statistical concepts alongside some general knowledge to lighten what is sometimes a very arid subject. The description of concepts with graphs and figures support the visual learner. I thoroughly enjoyed the quick questions presented alongside the description of concepts to test understanding, with the answers at the end of chapter which linked to bullet point summaries, help to consolidate the concepts covered. I thought it was an excellent way for someone to start on their path to understanding this area. Finally, I particularly appreciated the last chapter with its focus on the work by our dear friend Doug Altman.' Professor Rafael Perera, Professor of Medical Statistics, University of Oxford, UK\u003cbr\u003e'This is an excellent introductory book for medical statistics. It's well written, easy to read, with some great examples of statistics in everyday clinical practice. The question and answer format is especially useful in reinforcing key concepts discussed in the chapter. There are lots of additional learning material included in the online resource for those seeking a more detailed understanding of the topic. The author is to be congratulated on making an important but difficult subject appear relatively straightforward and interesting to even the non-expert.' Professor Paul Banaszkiewicz, Consultant Orthopaedic Surgeon North East NHS Surgical Centre (NENSC), Gateshead, UK, and Visiting Professor Northumbria University, Newcastle-upon-Tyne, UK \u003cbr\u003e'The modern practice in orthopaedic and trauma surgery is a completely different practice to that which many of us grew up with and is now firmly founded on research and evidence. And this evidence itself is built around scientific method and statistical analysis. This excellent book provides a comprehensive guide to biostatistics for the orthopaedic surgeon and aspiring clinician scientist. Through clear explanations of complex concepts the author succeeds in simplifying the difficult and I am sure this will become an essential reference for all involved in orthopaedic surgery.' Professor Ben Ollivere, Professor of Orthopaedic Trauma, University of Nottingham, UK\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface; Acknowledgements; How to get the best out of this book; 1. Medicine and numbers: what is the connection?; 2. Measuring a variable: what is the difference between eye colour and height; 3. Summarising data: communicating easily; 4. Why average and range is not always enough: standard deviation and standard error; 5. The normal distribution: what's so 'normal' about it?; 6. Confidence interval: what is your guesstimate?; 7. Innocent until proven guilty! The null hypothesis; 8. Errors in hypothesis tests: learn your α from your β; 9. The randomized controlled trial: why does it have to be random?; 10. Choosing a statistical test: to t or not to t?; 11. Finding the odd one out: the ANOVA test; 12. Categorically different? The Chi-Squared test; 13. If the line fits: correlation and linear regression; 14. Hindsight is 20\/20: logistic regression; 15. Don't risk the odds. risk vs odds as the outcome measure; 16. I will survive! Time to event data analysis; 17. High-ceiling or low threshold? Accuracy of a diagnostic test; 18. Apples or oranges? Meta-analysis of selected studies; 19. Lies, damned lies and statistics: untangling facts from fiction!; Glossary; Appendix 1. Are you ready to test yourself? Single Best Answer questionnaire; Appendix 2. Software and practice problems; Appendix 3. Practice database; Appendix 4. References and further reading; Appendix 5. Further resources.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738343944535,"sku":"9781108978156","price":20.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781108978156.jpg?v=1723811953"},{"product_id":"public-health-disease-and-development-in-africa-9781138631250","title":"Public Health Disease and Development in Africa","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe closure of the Millennium Development Goals (MDGs) in 2015 prompted the need for a book of this kind. An interdisciplinary group of global health scholars contribute to the understanding of the emerging and fast-growing problem of the dual burden of communicable and non-communicable diseases (NCDs) in Africa. \u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThis book is timely, as the international community has moved from the MDGs to adopt the Sustainable Development Goals (SDGs) as the blueprint for a new human development agenda. Contributions and case studies are situated in the revised Epidemiologic and Nutrition Transition Model to capture the current situation, referencing communicable and NCDs on the African continent. The case studies encapsulated aim to help minimize negative health outcomes and improve population health, well-being, and equity in the future.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThis book will be significant in policy circles to assist international organizations, governments, and United Nations agencies. It a\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePART I: INTRODUCTION 1. Introduction: Africa’s Epidemiologic Transition of Dual Burden of Communicable and Non-communicable Diseases 2. Taking it Global: Towards an Index of Wellbeing for Low- to Middle-income Countries PART II: EMERGING AND RE-EMERGING INFECTIOUS DISEASES 3. Examining the West African Ebola Outbreak through the Application of the Disease Ecology Framework 4. Progress towards Combatting HIV\/AIDS in Africa 5. Progress towards Combatting Malaria in Africa 6. The Impact of Land Use and Land Cover Change on the Spatial Distribution of Buruli Ulcer in Southwest Ghana 7. Perilous Outcomes: The Intersection of Culture, Maternal Health, and HIV\/AIDS on Malawian Women in the Face of an International Development Consensus PART III: NONCOMMUNICABLE\/DEGENERATIVE DISEASE COMPLEX 8. Physical Activity, Nutrition, and Hypertension in Sub-Saharan Africa: The Case of Ghana and South Africa 9. Racial and Ethnic Differences in Non-Communicable Diseases in South Africa 10. Weight Status and Uncontrolled Urbanization in Cameroon: Current and Future Health Challenges 11. Maternal Perception about Early Childhood Caries in Nigeria 12. Health Data Collection Efforts and Non-Communicable Diseases: A Case Study in Uganda PART IV: FOOD SECURITY, NUTRITION, AND HEALTH 13. Nutritional and Nutraceutical Properties of Traditional African Foods 14. Multi-Level Participatory Approaches to Mobilize Dietary Diversity for Improved Infant and Young Child Feeding in Banana-Based Agri-Food Systems of Rural East Africa \u003c\/p\u003e","brand":"Taylor \u0026 Francis Ltd","offers":[{"title":"Default Title","offer_id":48738413216087,"sku":"9781138631250","price":135.0,"currency_code":"GBP","in_stock":true}]},{"product_id":"infectious-disease-epidemiology-theory-and-prac-theory-and-practice-9781284268843","title":"Infectious Disease Epidemiology Theory and Prac","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"Jones and Bartlett Publishers, Inc","offers":[{"title":"Default Title","offer_id":48738516304215,"sku":"9781284268843","price":93.6,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781284268843.jpg?v=1723812110"},{"product_id":"phase-six-9781529415094","title":"Phase Six","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003e\"Jim Shepard is a fiction writer of peculiar but tantalizing gifts.\"\u003c\/b\u003e \u003ci\u003e\u003cb\u003eThe New York Times\u003c\/b\u003e\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003eIn a tiny settlement on the west coast of Greenland, 11-year-old Aleq and his best friend, frequent trespassers at a mining site exposed to mountains of long-buried and thawing permafrost, carry what they pick up back into their village, and from there Shepard's harrowing and deeply moving story follows Aleq, one of the few survivors of the initial outbreak, through his identification and radical isolation as the likely index patient. While he shoulders both a crushing guilt for what he may have done and the hopes of a world looking for answers, we also meet two Epidemic Intelligence Service investigators dispatched from the CDC--Jeannine, an epidemiologist and daughter of Algerian immigrants, and Danice, an MD and lab wonk. As they attempt to head off the cataclysm, Jeannine--moving from the Greenland hospital overwhelmed with the first patients to a Level 4 high-security facility in the Rocky Mountains--does what she can to sustain Aleq.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eBoth a chamber piece of multiple intimate perspectives and a more omniscient glimpse into the megastructures (political, cultural, and biological) that inform such a disaster, the novel reminds us of the crucial bonds that form in the midst of catastrophe, as a child and several hyper-educated adults learn what it means to provide adequate support for those they love. In the process, they celebrate the precious worlds they might lose, and help to shape others that may survive.\u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eJim Shepard is a fiction writer of peculiar but tantalizing gifts.\u003c\/b\u003e * The New York Times *\u003cbr\u003e\u003cb\u003eIf you've been waiting for the great novel of the COVID-19 era, it's in your hands.\u003c\/b\u003e I read\u003ci\u003e Phase Six \u003c\/i\u003ewith a galloping heart. With heroic humor and a poet's ear and eye for what makes humanity worth saving, Shepard's polyphonic novel of contagion and collapse is also the story of love's unlikely survival in the most hostile conditions -- Karen Russell, author of Swamplandia!\u003cbr\u003e\u003cb\u003eJim Shepard not only writes at the cutting edge of literature, but he IS the cutting edge of literature\u003c\/b\u003e. He excavates the twin crises of our era-climate change and pathogens-and builds a story that is as poignant as it is true. The writing is stunning. The research is stunning. The after-effect is stunning\u003cb\u003e. \u003ci\u003ePhase Six\u003c\/i\u003e is a great book for our times: the past, the present and those that-we hope-are yet to come.\u003c\/b\u003e -- Colum McCann, author of Apeirogon\u003cbr\u003eNo amount of prior admiration for Jim Shepard's fiction prepared me for the magnificent \u003ci\u003ePhase Six\u003c\/i\u003e-a book \u003cb\u003eat once so wise and so funny, so bleak and so tender.\u003c\/b\u003e With astonishing virtuosity, he conveys huge amounts of information in a way that is not only lucid but utterly gripping, and he creates characters who make me want to rush into the novel to save them from the virus and themselves. \u003cb\u003eWhat a triumph!\u003c\/b\u003e -- Margot Livesey, author of The Boy in the Field\u003cbr\u003eImagining catastrophe is, now more than ever, an essential task, and no one does it better than Jim Shepard. \u003cb\u003eAt once scary and timely, funny and absorbing, \u003ci\u003ePhase Six \u003c\/i\u003eis a must-read.\u003c\/b\u003e -- Elizabeth Kolbert, author of Under a White Sky\u003cbr\u003e\u003cb\u003ePaced like a prophetic thriller\u003c\/b\u003e . . . Shepard has frequently employed research as a foundation for his literary creations, but never before in such pulse-racing fashion . . . Readers will find themselves in territory that feels eerily familiar-panic, politics, uncertainty, fear, a resistance to quarantine, an overload of media noise-as Shepard's command of tone never lets the tension ease . . . \u003cb\u003eAll the narrative propulsion of escapist fiction without the escape.\u003c\/b\u003e * Kirkus Reviews (starred review) *\u003cbr\u003e\u003ci\u003ePhase Six\u003c\/i\u003e is a \u003cb\u003efast-paced, suspenseful story\u003c\/b\u003e about what happens when a different microbe is unleashed on the world . . . \u003cb\u003e[A]\u003c\/b\u003e\u003cb\u003en ode to family, friends, lovers, hard work and the beautiful, heartbreaking innocence of childhood\u003c\/b\u003e * Daily Mail *\u003cbr\u003e\u003cb\u003eThrilling\u003c\/b\u003e . . . \u003cb\u003ea very human story, full of \u003c\/b\u003e\u003cb\u003eemotion\u003c\/b\u003e and inevitable sorrow and pain. * Irish Indepedent *","brand":"Quercus Publishing","offers":[{"title":"Default Title","offer_id":48740279910743,"sku":"9781529415094","price":9.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781529415094.jpg?v=1720054299"},{"product_id":"dead-epidemiologists-on-the-origins-of-covid-19-9781583679036","title":"Dead Epidemiologists: On the Origins of COVID-19","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe COVID-19 pandemic shocked the world. It shouldn’t have. Since this century’s turn, epidemiologists have warned of new infectious diseases. Indeed, H1N1, H7N9, SARS, MERS, Ebola Makona, Zika, and a variety of lesser viruses have emerged almost annually. But what of the epidemiologists themselves? Some bravely descended into the caves where bat species hosted coronaviruses, including the strains that evolved into the COVID-19 virus. Yet, despite their own warnings, many of the researchers appear unable to understand the true nature of the disease—as if they are dead to what they’ve seen.  Dead Epidemiologists is an eclectic collection of commentaries, articles, and interviews revealing the hidden-in-plain-sight truth behind the pandemic: Global capital drove the deforestation and development that exposed us to new pathogens. Rob Wallace and his colleagues—ecologists, geographers, activists, and, yes, epidemiologists—unpack the material and conceptual origins of COVID-19. From deepest Yunnan to the boardrooms of New York City, this book offers a compelling diagnosis of the roots of COVID-19, and a stark prognosis of what—without further intervention—may come.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eCrafting in real time a political-economic ecology of pandemics in the age of climate change and agribusiness. — Edgar Rivera Colón, coauthor, Principles and Practice of Narrative Medicine \/\/ This is a book of truth, that kind that sets us free by cutting through the bindings of lies and ignorance. In this moment of cascading crises, it is necessary to find the truth, which is never what’s on the surface. We are fortunate, indeed, that Rob Wallace has been preparing for now, plunging into subjects as varied as ecology and political economy so that he can articulate the scope of our problems. That he can see the truth is amazing. That he can write about it with grace and humor eases the shock of seeing the real through the haze of our false consciousness. Read this book as if your life depended on it, because it does. — Mindy Thompson Fullilove, author, Main Street: How a City’s Heart Connects Us All \/\/ Name one other epidemiologist who knows his N.K. Jemisin as well as his Gramsci and Arrighi, who understands the broad colonial relations of corporate capitalism as well as the detailed “epizoological perversities” of the factory farm—and who can write about it all with such perfect, pissed-off, punk-rock eloquence and fury. In his brilliance and in the extraordinary depth, range, and courage of his thinking, Rob Wallace is unique. From the plantation-era roots of the contemporary horseshoe-crab-blood-mining industry—yeah, you read that right—to the reproductive cycle of the Chinese horseshoe bat, Dead Epidemiologists makes sense of the COVID-19 pandemic like no other work I’ve encountered anywhere, as a disease that exists in and arose out of the globalized dystopia in which we already live. This is radical thinking in the very best sense: Wallace is unwilling to accept the rigged and homicidal terms of the world we’ve been given. He insists on no less than the birthing of a new one, or better yet, a return, in solidarity, humility, and love, to the planet that we already have.— Ben Ehrenreich, author, Desert Notebooks: A Road Map for the End of Time \/\/ If Big Farms Make Big Flu was an eye-opener, Dead Epidemiologists has taken the analysis to a completely different level of sophistication. The breadth and depth of issues considered with authority and perspicacity in the new collection of essays makes this book essential reading. It is also a devastating critique of the failures of mainstream epidemiologists. The scientific literature on COVID-19 and other pandemics largely ignores the role of capitalist production as “a causal factor in the production of invasive species.” This book sets the context for understanding how neoliberal capitalism is generating its own nemesis and threatening the annihilation of billions of people. But it also shelters hope in the organising capacity of peasant and small farmer movements. This book deserves to be in everyone’s hands. — Firoze Manji, host, Organising in the Times of COVID-19, Daraja Press","brand":"Monthly Review Press,U.S.","offers":[{"title":"Default Title","offer_id":48740542447959,"sku":"9781583679036","price":66.5,"currency_code":"GBP","in_stock":false}]},{"product_id":"challenging-health-inequalities-from-acheson-to-choosing-health-9781861348999","title":"Challenging health inequalities: From Acheson to","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book offers a unique multi-disciplinary perspective on tackling health inequalities in a rich country, examining the New Labour policy agenda for tackling health inequalities and its inherent challenges. The book presents an overview of progress since the publication of the seminal and ambitious 1998 Acheson Inquiry into health inequalities, and the theoretical and methodological issues underpinning health inequalities. The contributors consider the determinants of inequality - for example, early childhood experience and ethnicity - the factors that mediate the relationship between determinants and health - nutrition, housing and health behaviour - and the sectoral policy interventions in user involvement, local area partnership working and social work. Challenging health inequalities offers a combination of broad analysis of progress from differing perspectives and will be key reading to academics, students and policy makers.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"the book benefits from bringing together a wide range of professional and academic experiences that make a valuable contribution to addressing these issues in a contemporary society ... I would recommend this book as a valuable reference resource for departments, teams or organisations\" www.pcx.nhs.uk - NHS Patient-Citizen Exchange Newsletter, December 2007\u003cbr\u003e\"An excellent, much needed textbook that provides a critical overview of the health inequalities agenda today and what progress has\/has not been made.\" Dr Anne Confopoutos, Liverpool Hope University\u003cbr\u003e\"..adds further depth and breadth to our understanding of health inequalities and policies to address them...\"  Sociology of Health \u0026amp; Illness, Vol 30:3, 2008\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eChallenging health inequalities: introduction ~ Nick Spencer and Elizabeth Dowler; Progress in tackling health inequalities: a policy maker's perspective ~ Ray Earwicker; Inequalities in mortality rates under New Labour ~ Danny Dorling, Mary Shaw and George Davey Smith; Explaining inequalities in health: theoretical, conceptual and methodological agendas ~ Simon Williams, Michael Calnan and Alan Dolan; Inequalities in pregnancy and early years and the impact across the lifecourse: progress and future challenges ~ Nick Spencer and Catherine Law; Inequalities and ethnicity: evidence and intervention ~ Hannah Bradby and Tarani Chandola; Housing conditions and health ~ David Ormandy; Inequalities in food and nutrition: challenging 'lifestyles' ~ Elizabeth Dowler, Martin Caraher and Paul Lincoln; Behaving badly? Smoking and the role of behaviour change in tackling health inequalities ~ Nick Spencer; Health inequalities and user involvement ~ Jonathan Tritter and Helen Lester; Gilding the ghetto again? Community development approaches to tackling health inequalities ~ Mick Carpenter; A new agenda for social work: tackling health inequalities in physical health ~ Eileen McLeod, Paul Bywaters, Peter Beresford, Suzy Croft and Mark Drakeford; Challenging health inequalities: themes and issues ~ Elizabeth Dowler and Nick Spencer.","brand":"Bristol University Press","offers":[{"title":"Default Title","offer_id":48742380142935,"sku":"9781861348999","price":26.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781861348999.jpg?v=1720061157"},{"product_id":"clear-cutting-disease-control-capital-led-deforestation-public-health-austerity-and-vector-borne-infection-9783030102777","title":"Clear-Cutting Disease Control: Capital-Led","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe vector-borne Zika virus joins avian influenza, Ebola, and yellow fever as recent public health crises threatening pandemicity.\u003c\/p\u003e\u003cp\u003eBy a combination of stochastic modeling and economic geography, this book proposes two key causes together explain the explosive spread of the worst of the vector-borne outbreaks.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eEcosystems in which such pathogens are largely controlled by environmental stochasticity are being drastically streamlined by both agribusiness-led deforestation and deficits in public health and environmental sanitation.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003eConsequently, a subset of infections that once burned out relatively quickly in local forests are now propagating across susceptible human populations whose vulnerability to infection is often exacerbated in structurally adjusted cities. The resulting outbreaks are characterized by greater global extent, duration, and momentum.\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eAs infectious diseases in an age of nation states and global health programs cannot, as much of the present modeling literature presumes, be described by interacting populations of host, vector, and pathogen alone, a series of control theory models is also introduced here. These models, useful to researchers and health officials alike, explicitly address interactions between government ministries and the pathogens they aim to control.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe Social Context of the Emergence of Vector-Borne Disease.- Modeling Vector-Borne Diseases in a Commoditized Landscape.- Modeling State Interventions.- Implications for Disease Intervention and Modeling.- Mathematical Appendix.- References. \u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743024034135,"sku":"9783030102777","price":39.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"immunoepidemiology-9783030255527","title":"Immunoepidemiology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis textbook focuses on the nascent field of Immunoepidemiology that addresses how differences in immune responses among individuals affect the epidemiology of infectious diseases, cancer, hypersensitivity, and autoimmunity. The idea for the book originated from a course entitled “Immunology for Epidemiologists“ at the Yale School of Public Health. While many fine textbooks are available that address the immunological responses of individuals to pathogens, these provided very little information regarding how immunological variation among populations affects the epidemiology of disease. And yet, it has long been recognized that there is great immunologic diversity among people, which can have a profound effect on the epidemiology of disease. Careful review of the immunologic and epidemiologic literature revealed that there have been relatively few publications concerning immunoepidemiology and that no textbook is available on the subject. This textbook therefore aims to fill this void by providing a much-needed tool to comprehensively and efficiently teach immunoepidemiology. The book includes a section on the basic principles of immunology, and then applies them to particular examples of disease in human populations. The target audience for this text book are Masters of Public Health students.  Others who should also find it of interest include PhD students in epidemiology, immunology, medical students, generalists, and specialists in immunology, infectious diseases, cancer, and rheumatology.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSection I. Introduction​\u003cp\u003e\u003cb\u003eChapter 1. Introduction to Immunology, Epidemiology, and Immunoepidemiology\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eLinda Niccolai, Nancy H. Ruddle, and Peter J. Krause\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 2. Organization and Cells of the Immune System\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003ePaula B. Kavathas, PhD, Peter J. Krause, MD, Nancy H. Ruddle, PhD\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 3. Innate Immunity:  Recognition and Effector Functions\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePaula B. Kavathas, PhD, Peter J. Krause, MD, Nancy H. Ruddle, PhD\u003cb\u003e\u003cbr\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 4. Adaptive Immunity: Antigen Recognition by T and B Lymphocytes\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePaula B. Kavathas, PhD, Peter J. Krause, MD, Nancy H. Ruddle, PhD\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 5 Adaptive Immunity: Effector Functions, Regulation,  and Vaccination\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePaula B. Kavathas, PhD, Peter J. Krause, MD, Nancy H. Ruddle, PhD\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 6. Disorders of the Immune System\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePaula B. Kavathas, PhD, Peter J. Krause, MD, Nancy H. Ruddle, PhD\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 7.  Polymorphisms of Selected Components of the Innate and Adaptive Immune Systems\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eNancy H. Ruddle and Paula B. Kavathas\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 8. Immunoepidemiology of Immune Dysfunction\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eEric Meffre, Peter J. Krause and Nancy H. Ruddle\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 9. Immunoepidemiology of \u003ci\u003eMycobacterium tuberculosis\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eCamila D. Odio, Richard J. Bucala\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 10. Host Immunity to Human immunodeficiency Virus Infection\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eElijah Paintsil\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 11. Fungal Immunoepidemiology\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eMarwan M. Azar\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 12. Immunoepidemiology of \u003ci\u003ePlasmodium falciparum \u003c\/i\u003eMalaria\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eAmy K. Bei, Sunil Parikh\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 13. Immunoepidemiology of Cancer\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eXiaomei Ma, Rong Wang\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 14. Modeling Approaches Toward Understanding Infectious Disease Transmission\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eLaura A. Skrip, Jeffrey P. Townsend\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 15. Vaccines\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eDiane McMahon-Pratt\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChapter 16. Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003ePeter J. Krause, Paula B. Kavathas, Nancy H. Ruddle\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAppendix\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eJane O'Bryan, Kara Fikrig, Peter J. Krause, Kate Nyhan\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743028064599,"sku":"9783030255527","price":85.49,"currency_code":"GBP","in_stock":true}]},{"product_id":"methods-and-applications-of-sample-size-calculation-and-recalculation-in-clinical-trials-9783030495275","title":"Methods and Applications of Sample Size","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book provides an extensive overview of the principles and methods of sample size calculation and recalculation in clinical trials. Appropriate calculation of the required sample size is crucial for the success of clinical trials. At the same time, a sample size that is too small or too large is problematic due to ethical, scientific, and economic reasons. Therefore, state-of-the art methods are required when planning clinical trials. \u003c\/p\u003e  \u003cp\u003ePart I describes a general framework for deriving sample size calculation procedures. This enables an understanding of the common principles underlying the numerous methods presented in the following chapters. Part II addresses the fixed sample size design, where the required sample size is determined in the planning stage and is not changed afterwards. It covers sample size calculation methods for superiority, non-inferiority, and equivalence trials, as well as comparisons between two and more than two groups. A wide range of further topics is discussed, including sample size calculation for multiple comparisons, safety assessment, and multi-regional trials. There is often some uncertainty about the assumptions to be made when calculating the sample size upfront. Part III presents methods that allow to modify the initially specified sample size based on new information that becomes available during the ongoing trial. Blinded sample size recalculation procedures for internal pilot study designs are considered, as well as methods for sample size reassessment in adaptive designs that use unblinded data from interim analyses. The application is illustrated using numerous clinical trial examples, and software code implementing the methods is provided.\u003c\/p\u003e  \u003cp\u003eThe book offers theoretical background and practical advice for biostatisticians and clinicians from the pharmaceutical industry and academia who are involved in clinical trials. Covering basic as well as more advanced and recently developed methods, it is suitable for beginners, experienced applied statisticians, and practitioners. To gain maximum benefit, readers should be familiar with introductory statistics. The content of this book has been successfully used for courses on the topic.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e“The R source code is shown by chapter, well-documented, and easy to find and follow as brief descriptions and necessary specifications for the function calls are given by means of comments. … a wide area of application fields is covered and exhaustive literature references for further reading are given. … The presentation of the material is very reader-friendly, easily accessible and pedagogical … . It is likewise highly recommended … . This is an effective and nicely written reference textbook.” (Oke Gerke, ISCB News, iscb.info, Vol. 72, December, 2021)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003ePart I Basics\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e1        \u003c\/b\u003e\u003cb\u003eIntroduction\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e1.1       Background and outline\u003c\/p\u003e  \u003cp\u003e1.2       Examples\u003c\/p\u003e  \u003cp\u003e1.2.1        The ChroPac trial\u003c\/p\u003e  \u003cp\u003e1.2.2        The Parkinson trial \u003c\/p\u003e  \u003cp\u003e1.3       General considerations when calculating sample sizes\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e2        \u003c\/b\u003e\u003cb\u003eStatistical test and sample size calculation\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e2.1       The main principle of statistical testing\u003c\/p\u003e  2.2       The main principle of sample size calculation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003ePart II Sample size calculation\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e3        \u003c\/b\u003e\u003cb\u003eComparison of two groups for normally distributed outcomes and test for difference or superiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e3.1       Background and notation\u003c\/p\u003e  \u003cp\u003e3.2       \u003ci\u003ez\u003c\/i\u003e-test\u003c\/p\u003e  \u003cp\u003e3.3       t-test\u003c\/p\u003e  \u003cp\u003e3.4       Analysis of covariance\u003c\/p\u003e  \u003cp\u003e3.5       Bayesian approach\u003c\/p\u003e  \u003cp\u003e3.5.1        Background\u003c\/p\u003e  \u003cp\u003e3.5.2        Methods\u003c\/p\u003e   \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e4        \u003c\/b\u003e\u003cb\u003eComparison of two groups for continuous and ordered categorical outcomes and test for difference or superiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e4.1       Background and notation\u003c\/p\u003e  \u003cp\u003e4.2       Continuous outcomes\u003c\/p\u003e  \u003cp\u003e4.3       Ordered categorical outcomes\u003c\/p\u003e  \u003cp\u003e4.3.1        Assumption-free approach\u003c\/p\u003e  \u003cp\u003e4.3.2        Assuming proportional odds\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e5        \u003c\/b\u003e\u003cb\u003eComparison of two groups for binary outcomes and test for difference and superiority\u003c\/b\u003e\u003c\/p\u003e  5.1       Background and notation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e5.2       Asymptotic tests\u003c\/p\u003e  \u003cp\u003e5.2.1        Difference of rates as effect measure\u003c\/p\u003e  5.2.2        Risk ratio as effect measure\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e5.2.3        Odds ratio as effect measure\u003c\/p\u003e  \u003cp\u003e5.2.4        Logistic regression\u003c\/p\u003e  5.3       Exact unconditional tests\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e5.3.1        Background\u003c\/p\u003e  \u003cp\u003e5.3.2        Fisher-Boschloo test\u003c\/p\u003e   \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e6        \u003c\/b\u003e\u003cb\u003eComparison of two groups for time-to-event outcomes and test for differences or superiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e6.1       Background and notation\u003c\/p\u003e  \u003cp\u003e6.1.1        Time-to-event data\u003c\/p\u003e  \u003cp\u003e6.1.2        Sample size calculation for time-to-event data\u003c\/p\u003e  \u003cp\u003e6.2       Exponentially distributed time-to-event data\u003c\/p\u003e  \u003cp\u003e6.3       Time-to-event data with proportional hazards\u003c\/p\u003e  \u003cp\u003e6.3.1        Approach of Schoenfeld\u003c\/p\u003e  \u003cp\u003e6.3.2        Approach of Freedman\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e7        \u003c\/b\u003e\u003cb\u003eComparison of more than two groups and test for difference\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e7.1       Background and notation\u003c\/p\u003e  \u003cp\u003e7.2       Normally distributed outcomes\u003c\/p\u003e  \u003cp\u003e7.3       Continuous outcomes\u003c\/p\u003e  \u003cp\u003e7.4       Binary outcomes \u003c\/p\u003e  \u003cp\u003e7.4.1        Analysis with chi-square test\u003c\/p\u003e  \u003cp\u003e7.4.2        Analysis with Cochran-Armitage test\u003c\/p\u003e  \u003cp\u003e7.5       Time-to-event outcomes\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e8        \u003c\/b\u003e\u003cb\u003eComparison of two groups and test for non-inferiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e8.1       Background and notation\u003c\/p\u003e  \u003cp\u003e8.2       Normally distributed outcomes\u003c\/p\u003e  \u003cp\u003e8.2.1        Difference of means\u003c\/p\u003e  8.2.2        Ratio of means\u003cp\u003e\u003c\/p\u003e  8.3       Continuous and ordered categorical outcomes\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e8.4       Binary outcomes\u003c\/p\u003e  \u003cp\u003e8.4.1        Analysis with asymptotic tests\u003c\/p\u003e  \u003cp\u003e8.4.1.1  Difference of rates as effect measure\u003c\/p\u003e  \u003cp\u003e8.4.1.2  Risk ratio as effect measure\u003c\/p\u003e  8.4.1.3  Odds ratio as effect measure\u003cp\u003e\u003c\/p\u003e  8.4.2        Exact unconditional tests\u003cp\u003e\u003c\/p\u003e  8.4.2.1  Background\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e8.4.2.2  Difference of rates as effect measure\u003c\/p\u003e  \u003cp\u003e8.4.2.3  Risk ratio as effect measure\u003c\/p\u003e  \u003cp\u003e8.4.2.4  Odds ratio as effect measure\u003c\/p\u003e  \u003cp\u003e8.5       Time-to-event outcomes\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e9        \u003c\/b\u003eComparison of three groups in the gold standard non-inferiority design\u003c\/p\u003e  \u003cp\u003e9.1       Background and notation\u003c\/p\u003e  9.2       Net effect approach\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e9.3       Fraction effect approach\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e10    \u003c\/b\u003eComparison of two groups for normally distributed outcomes and test for equivalence\u003c\/p\u003e  \u003cp\u003e10.1   Background and notation\u003c\/p\u003e  \u003cp\u003e10.2   Difference of means\u003c\/p\u003e  10.3   Ratio of means\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e11    \u003c\/b\u003e\u003cb\u003eMultiple comparisons\u003c\/b\u003e\u003c\/p\u003e  11.1   Background and notation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e11.2   Generally applicable sample size calculation methods and applications\u003c\/p\u003e  \u003cp\u003e11.2.1    Methods\u003c\/p\u003e  \u003cp\u003e11.2.2    Applications\u003c\/p\u003e  \u003cp\u003e11.3   Multiple endpoints\u003c\/p\u003e  \u003cp\u003e11.3.1    Background and notation\u003c\/p\u003e  \u003cp\u003e11.3.2    Methods\u003c\/p\u003e  \u003cp\u003e11.4   More than two groups\u003c\/p\u003e  11.4.1    Background and notation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e11.4.2    Dunnett test\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e12    \u003c\/b\u003eAssessment of safety\u003c\/p\u003e  \u003cp\u003e12.1   Background and notation\u003c\/p\u003e  12.2   Testing hypotheses on the event probability\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e12.3   Estimating the occurrence probability of an event with specified precision\u003c\/p\u003e  \u003cp\u003e12.4   Observing at least one event\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e13    \u003c\/b\u003e\u003cb\u003eCluster-randomized trials\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e13.1   Background and notation\u003c\/p\u003e  \u003cp\u003e13.2   Normally distributed outcomes\u003c\/p\u003e  \u003cp\u003e13.2.1    Cluster-level analysis\u003c\/p\u003e  \u003cp\u003e13.2.2    Individual-level analysis\u003c\/p\u003e  \u003cp\u003e13.2.3    Dealing with unequal cluster size\u003c\/p\u003e  \u003cp\u003e13.3   Other scale levels of the outcome\u003c\/p\u003e  \u003cb\u003e \u003c\/b\u003e\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e14    \u003c\/b\u003e\u003cb\u003eMulti-regional trials\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e14.1   Background and notation\u003c\/p\u003e  \u003cp\u003e14.2   Sample size calculation for demonstrating consistency of global results and results for a specified region\u003c\/p\u003e  \u003cp\u003e14.3   Sample size calculation for demonstrating a consistent trend across all regions\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e15    \u003c\/b\u003e\u003cb\u003eIntegrated planning of phase II\/III drug development programs\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e15.1   Background and notation\u003c\/p\u003e  \u003cp\u003e15.2   Optimizing phase II\/III programs\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e16    \u003c\/b\u003e\u003cb\u003eSimulation-based sample size calculation\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart III Sample size recalculation\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e17    \u003cb\u003eBackground\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart IIIA Blinded sample size recalculation in internal pilot study designs\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e18    \u003cb\u003eBackground and notation\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e19    \u003cb\u003eA general approach for controlling the type I error rate for blinded sample size recalculation\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cb\u003e20    \u003c\/b\u003e\u003cb\u003eComparison of two groups for normally distributed outcomes and test for difference or superiority\u003c\/b\u003e\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e20.1   \u003ci\u003et\u003c\/i\u003e-Test\u003c\/p\u003e  \u003cp\u003e20.1.1    Background and notation\u003c\/p\u003e  \u003cp\u003e20.1.2    Blinded variance estimation\u003c\/p\u003e  20.1.3    Type I error rate\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e20.1.4    Power and sample size\u003c\/p\u003e  \u003cp\u003e20.2   Analysis of covariance\u003c\/p\u003e  20.2.1    Background and notation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e20.2.2    Blinded variance estimation\u003c\/p\u003e  \u003cp\u003e20.2.3    Type I error rate\u003c\/p\u003e  20.2.4    Power and sample size\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e21    \u003cb\u003eComparison of two groups for binary outcomes and test for difference or superiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e21.1   Background and notation\u003c\/p\u003e  \u003cp\u003e21.2   Asymptotic tests\u003c\/p\u003e  21.2.1    Difference of rates as effect measure\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e21.2.2    Risk ratio and odds ratio as effect measure\u003c\/p\u003e  \u003cp\u003e21.3   Fisher-Boschloo test\u003c\/p\u003e   \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e22    \u003c\/b\u003e\u003cb\u003eComparison of two groups for normally distributed outcomes and test for non-inferiority\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e22.1   \u003ci\u003et\u003c\/i\u003e-Test\u003c\/p\u003e  22.1.1    Background and notation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e22.1.2    Blinded variance estimation\u003c\/p\u003e  \u003cp\u003e22.1.3    Type I error rate\u003c\/p\u003e  22.1.4    Power and sample size\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e22.2   Analysis of covariance\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e23    \u003c\/b\u003eComparison of two groups for binary outcomes and test for non-inferiority\u003c\/p\u003e  \u003cp\u003e23.1   Background and notation\u003c\/p\u003e  \u003cp\u003e23.2   Difference of rates as effect measure\u003c\/p\u003e  \u003cp\u003e23.3   Risk ratio and odds ratio as effect measure\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e24    \u003c\/b\u003e\u003cb\u003eComparison of two groups for normally distributed outcomes and test for equivalence\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e25    \u003cb\u003eRegulatory and operational aspects\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e26    \u003c\/b\u003e\u003cb\u003eConcluding remarks\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart IIIB Unblinded sample size recalculation in adaptive designs\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e27    \u003c\/b\u003e\u003cb\u003eBackground and notation\u003c\/b\u003e\u003c\/p\u003e  27.1   Group-sequential designs\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e27.2   Adaptive designs\u003c\/p\u003e  \u003cp\u003e27.2.1    Combination function approach\u003c\/p\u003e  27.2.2    Conditional error function approach\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e28    \u003cb\u003eSample size recalculation based on conditional power\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e28.1   Background and notation\u003c\/p\u003e  \u003cp\u003e28.2   Using the interim estimate of the effect\u003c\/p\u003e  28.3   Using the initially specified effect\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e28.4   Using prior information as well as the interim effect estimate\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003e29    \u003c\/b\u003eSample size recalculation by optimization\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e30    \u003c\/b\u003e\u003cb\u003eRegulatory and operational aspects\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e31    \u003c\/b\u003eConcluding remarks\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eAppendix: Selected R software code\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eReferences\u003c\/b\u003e\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743037829463,"sku":"9783030495275","price":71.24,"currency_code":"GBP","in_stock":true}]},{"product_id":"predictive-models-for-decision-support-in-the-covid-19-crisis-9783030619121","title":"Predictive Models for Decision Support in the","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eCOVID-19 has hit the world unprepared, as the deadliest pandemic of the century. Governments and authorities, as leaders and decision makers fighting the virus, enormously tap into the power of artificial intelligence and its predictive models for urgent decision support. This book showcases a collection of important predictive models that used during the pandemic, and discusses and compares their efficacy and limitations.\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eReaders from both healthcare industries and academia can gain unique insights on how predictive models were designed and applied on epidemic data. Taking COVID19 as a case study and showcasing the lessons learnt, this book will enable readers to be better prepared in the event of virus epidemics or pandemics in the future.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e“This book is … of great interest for mathematical modelers--it nicely summarizes many important tools, with concrete examples, that could be adapted for other situations. … I strongly recommend this book to advanced undergraduate engineers and mathematicians as well as specialists dealing with dynamical system modeling.” (Arturo Ortiz-Tapia, Computing Reviews, July 26, 2022)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eChapter 1. Prediction for Decision Support during the COVID-19 Pandemic.- Chapter 2. Epidemiology Compartmental Models - SIR, SEIR and SEIR with Intervention.- Chapter 3. Forecasting COVID-19 Time Series based on an Auto Regressive Model.- Chapter 4. Nonlinear Prediction for the COVID-19 Data based on Quadratic Kalman Filtering.- Chapter 5. Artificial Intelligence Prediction for the COVID-19 Data based on LSTM Neural Networks and H2O AutoML.- Chapter 6. Predicting the Geographic Spread of the COVID-19 Pandemic: a case study from Brazil.","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743042318679,"sku":"9783030619121","price":54.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"fundamentals-of-clinical-trials-9783319185385","title":"Fundamentals of Clinical Trials","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis is the fifth edition of a very successful textbook on clinical trials methodology, written by recognized leaders who have long and extensive experience in all areas of clinical trials. The three authors of the first four editions have been joined by two others who add great expertise. A chapter on regulatory issues has been included and the chapter on data monitoring has been split into two and expanded. Many contemporary clinical trial examples have been added. There is much new material on adverse events, adherence, issues in analysis, electronic data, data sharing and international trials.\u003c\/p\u003e\u003cp\u003eThis book is intended for the clinical researcher who is interested in designing a clinical trial and developing a protocol. It is also of value to researchers and practitioners who must critically evaluate the literature of published clinical trials and assess the merits of each trial and the implications for the care and treatment of patients. The authors use numerous examples of published clinical trials to illustrate the fundamentals.\u003c\/p\u003e\u003cp\u003eThe text is organized sequentially from defining the question to trial closeout. One chapter is devoted to each of the critical areas to aid the clinical trial researcher. These areas include pre-specifying the scientific questions to be tested and appropriate outcome measures, determining the organizational structure, estimating an adequate sample size, specifying the randomization procedure, implementing the intervention and visit schedules for participant evaluation, establishing an interim data and safety monitoring plan, detailing the final analysis plan and reporting the trial results according to the pre-specified objectives.\u003c\/p\u003e\u003cp\u003eAlthough a basic introductory statistics course is helpful in maximizing the benefit of this book, a researcher or practitioner with limited statistical background would still find most if not all the chapters understandable and helpful. While the technical material has been kept to a minimum, the statistician may still find the principles and fundamentals presented in this text useful.   \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“This book aims to assist investigators in improving the quality of their clinical trials and protocols by discussing fundamental concepts with examples and in-depth review of the literature. … This is a valuable resource for students, clinicians, and researchers who are interested in designing a clinical trial or in critically appraising the published literature on clinical trials.” (Pooja Sethi, Doody’s Book Reviews, December, 2015)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eIntroduction to Clinical Trials.- Ethical Issues.- What is the Question?.- Study Population.- Basic Study Design.- The Randomization Process.- Blinding.- Sample Size.- Baseline Assessment.- Recruitment of Study Participants.- Data Collection and Quality Control.- Assessment and Reporting of Harm.- Assessment of Health Related Quality of Life.- Participant Adherence.- Survival Analysis.- Monitoring Committee Structure \u0026amp; Function.- Statistical Methods Used in Interim Monitoring.- Issues in Data Analysis.- Closeout.- Reporting and Interpreting of Results.- Multicenter Trials.- Regulatory Issues.\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":48743092748631,"sku":"9783319185385","price":58.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783319185385.jpg?v=1720064077"},{"product_id":"chemometrics-with-r-multivariate-data-analysis-in-the-natural-and-life-sciences-9783662620267","title":"Chemometrics with R: Multivariate Data Analysis","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book offers readers an accessible introduction to the world of multivariate statistics in the life sciences, providing a comprehensive description of the general data analysis paradigm, from exploratory analysis (principal component analysis, self-organizing maps and clustering) to modeling (classification, regression) and validation (including variable selection). It also includes a special section discussing several more specific topics in the area of chemometrics, such as outlier detection, and biomarker identification. The corresponding R code is provided for all the examples in the book; and scripts, functions and data are available in a separate R package. This second revised edition features not only updates on many of the topics covered, but also several sections of new material (e.g., on handling missing values in PCA, multivariate process monitoring and batch correction).\u003c\/p\u003e  \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eIntroduction. - Data.- Preprocessing.- Principal Component Analysis.- Self-Organizing Maps. - Clustering.- Classification.- Multivariate Regression. - Validation.- Variable Selection.- Chemometric Applications.\u003c\/p\u003e","brand":"Springer-Verlag Berlin and Heidelberg GmbH \u0026 Co. KG","offers":[{"title":"Default Title","offer_id":48743142523223,"sku":"9783662620267","price":54.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"textbook-of-clinical-epidemiology-for-medical-students-9789819936212","title":"Textbook of Clinical Epidemiology: For Medical","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book is a comprehensive and practical introduction of clinical epidemiology for students and practitioners. It covers both the basic principles and concepts of clinical epidemiology as well as its applications in various medical disciplines.\u003c\/p\u003e\u003cp\u003eIt covers how to design, conduct, and interpret clinical studies using methods such as bias analysis, confounding control, causality assessment, diagnosis evaluation, prognosis prediction treatment comparison, and meta-analysis in this book. It also introduces how to apply these skills to real-world scenarios through case studies and examples that provide a fresh perspective on familiar topics.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eThis book is a useful textbook for graduate and undergraduate students in medical schools, including MBBS (Bachelor of Medicine and Bachelor of Surgery) student.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1. Introduction.- Chapter 2. Distribution of Disease.- Chapter 3. Descriptive Study.- Chapter 4. Cohort Study.- Chapter 5. Case-Control Studies.- Chapter 6. Experimental Epidemiology.- Chapter 7. Screening and Diagnostic Tests.- Chapter 8. Bias.- Chapter 9. Cause of Disease and Causal Inference.- Chapter 10. Disease Prevention and Surveillance.- Chapter 11.  Communicable Diseases Epidemiology.- Chapter 12. Epidemiology of Non-communicable Diseases.- Chapter 13. Epidemiology of Public Health Emergencies.- Chapter 14. Molecular Epidemiology.- Chapter 15. Pharmacoepidemiology.- Chapter 16. Evidence-based Medicine and Systematic Review.- Chapter 17. Disease Prognosis.- Chapter 18. Nosocomial Infections.- Chapter 19. Epidemiology Design in Clinical Research.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":48743302037847,"sku":"9789819936212","price":66.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789819936212.jpg?v=1720065000"},{"product_id":"gordis-epidemiology-9780323877756","title":"Gordis Epidemiology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48864432095575,"sku":"9780323877756","price":41.79,"currency_code":"GBP","in_stock":true}]},{"product_id":"bayesian-biostatistics-9780470018231","title":"Bayesian Biostatistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e* This book provides an authoritative account of Bayesian methodology, from its most basic elements to its practical implementations, with an emphasis on healthcare techniques.     * Contains introductory explanations of Bayesian principles common to all areas.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“In conclusion, we consider the book by Lesaffre and Lawson a noteworthy contribution to the dissemination of Bayesian methods, and a good manual of reference for many common and some specialized applications in biomedical research. The great variety of examples and topics covered offers both advantages and disadvantages. Some parts might be too specialized for statistics students, but lecturers and applied statisticians will benefit a lot from the authors’ wealth of experience.”  (\u003ci\u003eBiometrical Journal\u003c\/i\u003e, 15 July 2013)\u003c\/p\u003e \u003cp\u003e\u003cb\u003e“\u003c\/b\u003eThe book Bayesian Biostatisticsby Lesaffre and Lawson, is a welcoming addition to this important area of research in biostatistical applications. For example, in the area of clinical trials, Bayesian methods provide flexibility and benefits for incorporating historical data with current data and then using the resulting posterior to make probability statements for different outcomes\u003cb\u003e”.\u003c\/b\u003e\u003cb\u003e(\u003c\/b\u003e\u003ci\u003eJournal of Biopharmaceutical Statistics\u003c\/i\u003e\u003cb\u003e,\u003c\/b\u003e 1 January 2013)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eNotation, terminology and some guidance for reading the book xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Basic Concepts in Bayesian Methods\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Modes of statistical inference 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 The frequentist approach: A critical reflection 4\u003c\/p\u003e \u003cp\u003e1.1.1 The classical statistical approach 4\u003c\/p\u003e \u003cp\u003e1.1.2 The \u003ci\u003eP\u003c\/i\u003e-value as a measure of evidence 5\u003c\/p\u003e \u003cp\u003e1.1.3 The confidence interval as a measure of evidence 8\u003c\/p\u003e \u003cp\u003e1.1.4 An historical note on the two frequentist paradigms\u003csup\u003e∗\u003c\/sup\u003e 8\u003c\/p\u003e \u003cp\u003e1.2 Statistical inference based on the likelihood function 10\u003c\/p\u003e \u003cp\u003e1.2.1 The likelihood function 10\u003c\/p\u003e \u003cp\u003e1.2.2 The likelihood principles 11\u003c\/p\u003e \u003cp\u003e1.3 The Bayesian approach: Some basic ideas 14\u003c\/p\u003e \u003cp\u003e1.3.1 Introduction 14\u003c\/p\u003e \u003cp\u003e1.3.2 Bayes theorem – discrete version for simple events 15\u003c\/p\u003e \u003cp\u003e1.4 Outlook 18\u003c\/p\u003e \u003cp\u003eExercises 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Bayes theorem: Computing the posterior distribution 20\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 20\u003c\/p\u003e \u003cp\u003e2.2 Bayes theorem – the binary version 20\u003c\/p\u003e \u003cp\u003e2.3 Probability in a Bayesian context 21\u003c\/p\u003e \u003cp\u003e2.4 Bayes theorem – the categorical version 22\u003c\/p\u003e \u003cp\u003e2.5 Bayes theorem – the continuous version 23\u003c\/p\u003e \u003cp\u003e2.6 The binomial case 24\u003c\/p\u003e \u003cp\u003e2.7 The Gaussian case 30\u003c\/p\u003e \u003cp\u003e2.8 The Poisson case 36\u003c\/p\u003e \u003cp\u003e2.9 The prior and posterior distribution of \u003ci\u003eh\u003c\/i\u003e(θ) 40\u003c\/p\u003e \u003cp\u003e2.10 Bayesian versus likelihood approach 40\u003c\/p\u003e \u003cp\u003e2.11 Bayesian versus frequentist approach 41\u003c\/p\u003e \u003cp\u003e2.12 The different modes of the Bayesian approach 41\u003c\/p\u003e \u003cp\u003e2.13 An historical note on the Bayesian approach 42\u003c\/p\u003e \u003cp\u003e2.14 Closing remarks 44\u003c\/p\u003e \u003cp\u003eExercises 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Introduction to Bayesian inference 46\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 46\u003c\/p\u003e \u003cp\u003e3.2 Summarizing the posterior by probabilities 46\u003c\/p\u003e \u003cp\u003e3.3 Posterior summary measures 47\u003c\/p\u003e \u003cp\u003e3.3.1 Characterizing the location and variability of the posterior distribution 47\u003c\/p\u003e \u003cp\u003e3.3.2 Posterior interval estimation 49\u003c\/p\u003e \u003cp\u003e3.4 Predictive distributions 51\u003c\/p\u003e \u003cp\u003e3.4.1 The frequentist approach to prediction 52\u003c\/p\u003e \u003cp\u003e3.4.2 The Bayesian approach to prediction 53\u003c\/p\u003e \u003cp\u003e3.4.3 Applications 54\u003c\/p\u003e \u003cp\u003e3.5 Exchangeability 58\u003c\/p\u003e \u003cp\u003e3.6 A normal approximation to the posterior 60\u003c\/p\u003e \u003cp\u003e3.6.1 A Bayesian analysis based on a normal approximation to the likelihood 60\u003c\/p\u003e \u003cp\u003e3.6.2 Asymptotic properties of the posterior distribution 62\u003c\/p\u003e \u003cp\u003e3.7 Numerical techniques to determine the posterior 63\u003c\/p\u003e \u003cp\u003e3.7.1 Numerical integration 63\u003c\/p\u003e \u003cp\u003e3.7.2 Sampling from the posterior 65\u003c\/p\u003e \u003cp\u003e3.7.3 Choice of posterior summary measures 72\u003c\/p\u003e \u003cp\u003e3.8 Bayesian hypothesis testing 72\u003c\/p\u003e \u003cp\u003e3.8.1 Inference based on credible intervals 72\u003c\/p\u003e \u003cp\u003e3.8.2 The Bayes factor 74\u003c\/p\u003e \u003cp\u003e3.8.3 Bayesian versus frequentist hypothesis testing 76\u003c\/p\u003e \u003cp\u003e3.9 Closing remarks 78\u003c\/p\u003e \u003cp\u003eExercises 79\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 More than one parameter 82\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 82\u003c\/p\u003e \u003cp\u003e4.2 Joint versus marginal posterior inference 83\u003c\/p\u003e \u003cp\u003e4.3 The normal distribution with \u003ci\u003eμ\u003c\/i\u003e and \u003ci\u003eσ\u003c\/i\u003e\u003csup\u003e2\u003c\/sup\u003e unknown 83\u003c\/p\u003e \u003cp\u003e4.3.1 No prior knowledge on \u003ci\u003eμ\u003c\/i\u003e and \u003ci\u003eσ\u003c\/i\u003e\u003csup\u003e2\u003c\/sup\u003e is available 84\u003c\/p\u003e \u003cp\u003e4.3.2 An historical study is available 86\u003c\/p\u003e \u003cp\u003e4.3.3 Expert knowledge is available 88\u003c\/p\u003e \u003cp\u003e4.4 Multivariate distributions 89\u003c\/p\u003e \u003cp\u003e4.4.1 The multivariate normal and related distributions 89\u003c\/p\u003e \u003cp\u003e4.4.2 The multinomial distribution 90\u003c\/p\u003e \u003cp\u003e4.5 Frequentist properties of Bayesian inference 92\u003c\/p\u003e \u003cp\u003e4.6 Sampling from the posterior distribution: The Method of Composition 93\u003c\/p\u003e \u003cp\u003e4.7 Bayesian linear regression models 96\u003c\/p\u003e \u003cp\u003e4.7.1 The frequentist approach to linear regression 96\u003c\/p\u003e \u003cp\u003e4.7.2 A noninformative Bayesian linear regression model 97\u003c\/p\u003e \u003cp\u003e4.7.3 Posterior summary measures for the linear regression model 98\u003c\/p\u003e \u003cp\u003e4.7.4 Sampling from the posterior distribution 99\u003c\/p\u003e \u003cp\u003e4.7.5 An informative Bayesian linear regression model 101\u003c\/p\u003e \u003cp\u003e4.8 Bayesian generalized linear models 101\u003c\/p\u003e \u003cp\u003e4.9 More complex regression models 102\u003c\/p\u003e \u003cp\u003e4.10 Closing remarks 102\u003c\/p\u003e \u003cp\u003eExercises 102\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Choosing the prior distribution 104\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 104\u003c\/p\u003e \u003cp\u003e5.2 The sequential use of Bayes theorem 104\u003c\/p\u003e \u003cp\u003e5.3 Conjugate prior distributions 106\u003c\/p\u003e \u003cp\u003e5.3.1 Univariate data distributions 106\u003c\/p\u003e \u003cp\u003e5.3.2 Normal distribution – mean and variance unknown 109\u003c\/p\u003e \u003cp\u003e5.3.3 Multivariate data distributions 110\u003c\/p\u003e \u003cp\u003e5.3.4 Conditional conjugate and semiconjugate distributions 111\u003c\/p\u003e \u003cp\u003e5.3.5 Hyperpriors 112\u003c\/p\u003e \u003cp\u003e5.4 Noninformative prior distributions 113\u003c\/p\u003e \u003cp\u003e5.4.1 Introduction 113\u003c\/p\u003e \u003cp\u003e5.4.2 Expressing ignorance 114\u003c\/p\u003e \u003cp\u003e5.4.3 General principles to choose noninformative priors 115\u003c\/p\u003e \u003cp\u003e5.4.4 Improper prior distributions 119\u003c\/p\u003e \u003cp\u003e5.4.5 Weak\/vague priors 120\u003c\/p\u003e \u003cp\u003e5.5 Informative prior distributions 121\u003c\/p\u003e \u003cp\u003e5.5.1 Introduction 121\u003c\/p\u003e \u003cp\u003e5.5.2 Data-based prior distributions 121\u003c\/p\u003e \u003cp\u003e5.5.3 Elicitation of prior knowledge 122\u003c\/p\u003e \u003cp\u003e5.5.4 Archetypal prior distributions 126\u003c\/p\u003e \u003cp\u003e5.6 Prior distributions for regression models 129\u003c\/p\u003e \u003cp\u003e5.6.1 Normal linear regression 129\u003c\/p\u003e \u003cp\u003e5.6.2 Generalized linear models 131\u003c\/p\u003e \u003cp\u003e5.6.3 Specification of priors in Bayesian software 134\u003c\/p\u003e \u003cp\u003e5.7 Modeling priors 134\u003c\/p\u003e \u003cp\u003e5.8 Other regression models 136\u003c\/p\u003e \u003cp\u003e5.9 Closing remarks 136\u003c\/p\u003e \u003cp\u003eExercises 137\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Markov chain Monte Carlo sampling 139\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 139\u003c\/p\u003e \u003cp\u003e6.2 The Gibbs sampler 140\u003c\/p\u003e \u003cp\u003e6.2.1 The bivariate Gibbs sampler 140\u003c\/p\u003e \u003cp\u003e6.2.2 The general Gibbs sampler 146\u003c\/p\u003e \u003cp\u003e6.2.3 Remarks\u003csup\u003e∗\u003c\/sup\u003e 150\u003c\/p\u003e \u003cp\u003e6.2.4 Review of Gibbs sampling approaches 152\u003c\/p\u003e \u003cp\u003e6.2.5 The Slice sampler\u003csup\u003e∗\u003c\/sup\u003e 153\u003c\/p\u003e \u003cp\u003e6.3 The Metropolis(–Hastings) algorithm 154\u003c\/p\u003e \u003cp\u003e6.3.1 The Metropolis algorithm 155\u003c\/p\u003e \u003cp\u003e6.3.2 The Metropolis–Hastings algorithm 157\u003c\/p\u003e \u003cp\u003e6.3.3 Remarks\u003csup\u003e∗\u003c\/sup\u003e 159\u003c\/p\u003e \u003cp\u003e6.3.4 Review of Metropolis(–Hastings) approaches 161\u003c\/p\u003e \u003cp\u003e6.4 Justification of the MCMC approaches\u003csup\u003e∗\u003c\/sup\u003e 162\u003c\/p\u003e \u003cp\u003e6.4.1 Properties of the MH algorithm 164\u003c\/p\u003e \u003cp\u003e6.4.2 Properties of the Gibbs sampler 165\u003c\/p\u003e \u003cp\u003e6.5 Choice of the sampler 165\u003c\/p\u003e \u003cp\u003e6.6 The Reversible Jump MCMC algorithm\u003csup\u003e∗\u003c\/sup\u003e 168\u003c\/p\u003e \u003cp\u003e6.7 Closing remarks 172\u003c\/p\u003e \u003cp\u003eExercises 173\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Assessing and improving convergence of the Markov chain 175\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 175\u003c\/p\u003e \u003cp\u003e7.2 Assessing convergence of a Markov chain 176\u003c\/p\u003e \u003cp\u003e7.2.1 Definition of convergence for a Markov chain 176\u003c\/p\u003e \u003cp\u003e7.2.2 Checking convergence of the Markov chain 176\u003c\/p\u003e \u003cp\u003e7.2.3 Graphical approaches to assess convergence 177\u003c\/p\u003e \u003cp\u003e7.2.4 Formal diagnostic tests 180\u003c\/p\u003e \u003cp\u003e7.2.5 Computing the Monte Carlo standard error 186\u003c\/p\u003e \u003cp\u003e7.2.6 Practical experience with the formal diagnostic procedures 188\u003c\/p\u003e \u003cp\u003e7.3 Accelerating convergence 189\u003c\/p\u003e \u003cp\u003e7.3.1 Introduction 189\u003c\/p\u003e \u003cp\u003e7.3.2 Acceleration techniques 189\u003c\/p\u003e \u003cp\u003e7.4 Practical guidelines for assessing and accelerating convergence 194\u003c\/p\u003e \u003cp\u003e7.5 Data augmentation 195\u003c\/p\u003e \u003cp\u003e7.6 Closing remarks 200\u003c\/p\u003e \u003cp\u003eExercises 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Software 202\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 WinBUGS and related software 202\u003c\/p\u003e \u003cp\u003e8.1.1 A first analysis 203\u003c\/p\u003e \u003cp\u003e8.1.2 Information on samplers 206\u003c\/p\u003e \u003cp\u003e8.1.3 Assessing and accelerating convergence 207\u003c\/p\u003e \u003cp\u003e8.1.4 Vector and matrix manipulations 208\u003c\/p\u003e \u003cp\u003e8.1.5 Working in batch mode 210\u003c\/p\u003e \u003cp\u003e8.1.6 Troubleshooting 212\u003c\/p\u003e \u003cp\u003e8.1.7 Directed acyclic graphs 212\u003c\/p\u003e \u003cp\u003e8.1.8 Add-on modules: GeoBUGS and PKBUGS 214\u003c\/p\u003e \u003cp\u003e8.1.9 Related software 214\u003c\/p\u003e \u003cp\u003e8.2 Bayesian analysis using SAS 215\u003c\/p\u003e \u003cp\u003e8.2.1 Analysis using procedure GENMOD 215\u003c\/p\u003e \u003cp\u003e8.2.2 Analysis using procedure MCMC 217\u003c\/p\u003e \u003cp\u003e8.2.3 Other Bayesian programs 220\u003c\/p\u003e \u003cp\u003e8.3 Additional Bayesian software and comparisons 221\u003c\/p\u003e \u003cp\u003e8.3.1 Additional Bayesian software 221\u003c\/p\u003e \u003cp\u003e8.3.2 Comparison of Bayesian software 222\u003c\/p\u003e \u003cp\u003e8.4 Closing remarks 222\u003c\/p\u003e \u003cp\u003eExercises 223\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Bayesian Tools for Statistical Modeling\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Hierarchical models 227\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 227\u003c\/p\u003e \u003cp\u003e9.2 The Poisson-gamma hierarchical model 228\u003c\/p\u003e \u003cp\u003e9.2.1 Introduction 228\u003c\/p\u003e \u003cp\u003e9.2.2 Model specification 229\u003c\/p\u003e \u003cp\u003e9.2.3 Posterior distributions 231\u003c\/p\u003e \u003cp\u003e9.2.4 Estimating the parameters 232\u003c\/p\u003e \u003cp\u003e9.2.5 Posterior predictive distributions 237\u003c\/p\u003e \u003cp\u003e9.3 Full versus empirical Bayesian approach 238\u003c\/p\u003e \u003cp\u003e9.4 Gaussian hierarchical models 240\u003c\/p\u003e \u003cp\u003e9.4.1 Introduction 240\u003c\/p\u003e \u003cp\u003e9.4.2 The Gaussian hierarchical model 240\u003c\/p\u003e \u003cp\u003e9.4.3 Estimating the parameters 241\u003c\/p\u003e \u003cp\u003e9.4.4 Posterior predictive distributions 243\u003c\/p\u003e \u003cp\u003e9.4.5 Comparison of FB and EB approach 244\u003c\/p\u003e \u003cp\u003e9.5 Mixed models 244\u003c\/p\u003e \u003cp\u003e9.5.1 Introduction 244\u003c\/p\u003e \u003cp\u003e9.5.2 The linear mixed model 244\u003c\/p\u003e \u003cp\u003e9.5.3 The generalized linear mixed model 248\u003c\/p\u003e \u003cp\u003e9.5.4 Nonlinear mixed models 253\u003c\/p\u003e \u003cp\u003e9.5.5 Some further extensions 256\u003c\/p\u003e \u003cp\u003e9.5.6 Estimation of the random effects and posterior predictive distributions 256\u003c\/p\u003e \u003cp\u003e9.5.7 Choice of the level-2 variance prior 258\u003c\/p\u003e \u003cp\u003e9.6 Propriety of the posterior 260\u003c\/p\u003e \u003cp\u003e9.7 Assessing and accelerating convergence 261\u003c\/p\u003e \u003cp\u003e9.8 Comparison of Bayesian and frequentist hierarchical models 263\u003c\/p\u003e \u003cp\u003e9.8.1 Estimating the level-2 variance 263\u003c\/p\u003e \u003cp\u003e9.8.2 ML and REml estimates compared with Bayesian estimates 264\u003c\/p\u003e \u003cp\u003e9.9 Closing remarks 265\u003c\/p\u003e \u003cp\u003eExercises 265\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Model building and assessment 267\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 267\u003c\/p\u003e \u003cp\u003e10.2 Measures for model selection 268\u003c\/p\u003e \u003cp\u003e10.2.1 The Bayes factor 268\u003c\/p\u003e \u003cp\u003e10.2.2 Information theoretic measures for model selection 274\u003c\/p\u003e \u003cp\u003e10.2.3 Model selection based on predictive loss functions 286\u003c\/p\u003e \u003cp\u003e10.3 Model checking 288\u003c\/p\u003e \u003cp\u003e10.3.1 Introduction 288\u003c\/p\u003e \u003cp\u003e10.3.2 Model-checking procedures 289\u003c\/p\u003e \u003cp\u003e10.3.3 Sensitivity analysis 295\u003c\/p\u003e \u003cp\u003e10.3.4 Posterior predictive checks 300\u003c\/p\u003e \u003cp\u003e10.3.5 Model expansion 308\u003c\/p\u003e \u003cp\u003e10.4 Closing remarks 316\u003c\/p\u003e \u003cp\u003eExercises 316\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Variable selection 319\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 319\u003c\/p\u003e \u003cp\u003e11.2 Classical variable selection 320\u003c\/p\u003e \u003cp\u003e11.2.1 Variable selection techniques 320\u003c\/p\u003e \u003cp\u003e11.2.2 Frequentist regularization 322\u003c\/p\u003e \u003cp\u003e11.3 Bayesian variable selection: Concepts and questions 325\u003c\/p\u003e \u003cp\u003e11.4 Introduction to Bayesian variable selection 326\u003c\/p\u003e \u003cp\u003e11.4.1 Variable selection for \u003ci\u003eK\u003c\/i\u003e small 326\u003c\/p\u003e \u003cp\u003e11.4.2 Variable selection for \u003ci\u003eK\u003c\/i\u003e large 330\u003c\/p\u003e \u003cp\u003e11.5 Variable selection based on Zellner’s \u003ci\u003eg\u003c\/i\u003e-prior 333\u003c\/p\u003e \u003cp\u003e11.6 Variable selection based on Reversible Jump Markov chain Monte Carlo 336\u003c\/p\u003e \u003cp\u003e11.7 Spike and slab priors 339\u003c\/p\u003e \u003cp\u003e11.7.1 Stochastic Search Variable Selection 340\u003c\/p\u003e \u003cp\u003e11.7.2 Gibbs Variable Selection 343\u003c\/p\u003e \u003cp\u003e11.7.3 Dependent variable selection using SSVS 345\u003c\/p\u003e \u003cp\u003e11.8 Bayesian regularization 345\u003c\/p\u003e \u003cp\u003e11.8.1 Bayesian LASSO regression 346\u003c\/p\u003e \u003cp\u003e11.8.2 Elastic Net and further extensions of the Bayesian LASSO 350\u003c\/p\u003e \u003cp\u003e11.9 The many regressors case 351\u003c\/p\u003e \u003cp\u003e11.10 Bayesian model selection 355\u003c\/p\u003e \u003cp\u003e11.11 Bayesian model averaging 357\u003c\/p\u003e \u003cp\u003e11.12 Closing remarks 359\u003c\/p\u003e \u003cp\u003eExercises 360\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Bayesian Methods in Practical Applications\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Bioassay 365\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Bioassay essentials 365\u003c\/p\u003e \u003cp\u003e12.1.1 Cell assays 365\u003c\/p\u003e \u003cp\u003e12.1.2 Animal assays 366\u003c\/p\u003e \u003cp\u003e12.2 A generic \u003ci\u003ein vitro\u003c\/i\u003e example 369\u003c\/p\u003e \u003cp\u003e12.3 Ames\/Salmonella mutagenic assay 371\u003c\/p\u003e \u003cp\u003e12.4 Mouse lymphoma assay (L5178Y TK+\/−) 373\u003c\/p\u003e \u003cp\u003e12.5 Closing remarks 374\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Measurement error 375\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Continuous measurement error 375\u003c\/p\u003e \u003cp\u003e13.1.1 Measurement error in a variable 375\u003c\/p\u003e \u003cp\u003e13.1.2 Two types of measurement error on the predictor in linear and nonlinear models 376\u003c\/p\u003e \u003cp\u003e13.1.3 Accommodation of predictor measurement error 378\u003c\/p\u003e \u003cp\u003e13.1.4 Nonadditive errors and other extensions 382\u003c\/p\u003e \u003cp\u003e13.2 Discrete measurement error 382\u003c\/p\u003e \u003cp\u003e13.2.1 Sources of misclassification 382\u003c\/p\u003e \u003cp\u003e13.2.2 Misclassification in the binary predictor 383\u003c\/p\u003e \u003cp\u003e13.2.3 Misclassification in a binary response 386\u003c\/p\u003e \u003cp\u003e13.3 Closing remarks 389\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Survival analysis 390\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Basic terminology 390\u003c\/p\u003e \u003cp\u003e14.1.1 Endpoint distributions 391\u003c\/p\u003e \u003cp\u003e14.1.2 Censoring 392\u003c\/p\u003e \u003cp\u003e14.1.3 Random effect specification 393\u003c\/p\u003e \u003cp\u003e14.1.4 A general hazard model 393\u003c\/p\u003e \u003cp\u003e14.1.5 Proportional hazards 394\u003c\/p\u003e \u003cp\u003e14.1.6 The Cox model with random effects 394\u003c\/p\u003e \u003cp\u003e14.2 The Bayesian model formulation 394\u003c\/p\u003e \u003cp\u003e14.2.1 A Weibull survival model 395\u003c\/p\u003e \u003cp\u003e14.2.2 A Bayesian AFT model 397\u003c\/p\u003e \u003cp\u003e14.3 Examples 397\u003c\/p\u003e \u003cp\u003e14.3.1 The gastric cancer study 397\u003c\/p\u003e \u003cp\u003e14.3.2 Prostate cancer in Louisiana: A spatial AFT model 401\u003c\/p\u003e \u003cp\u003e14.4 Closing remarks 406\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Longitudinal analysis 407\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15.1 Fixed time periods 407\u003c\/p\u003e \u003cp\u003e15.1.1 Introduction 407\u003c\/p\u003e \u003cp\u003e15.1.2 A classical growth-curve example 408\u003c\/p\u003e \u003cp\u003e15.1.3 Alternate data models 414\u003c\/p\u003e \u003cp\u003e15.2 Random event times 417\u003c\/p\u003e \u003cp\u003e15.3 Dealing with missing data 420\u003c\/p\u003e \u003cp\u003e15.3.1 Introduction 420\u003c\/p\u003e \u003cp\u003e15.3.2 Response missingness 421\u003c\/p\u003e \u003cp\u003e15.3.3 Missingness mechanisms 422\u003c\/p\u003e \u003cp\u003e15.3.4 Bayesian considerations 424\u003c\/p\u003e \u003cp\u003e15.3.5 Predictor missingness 424\u003c\/p\u003e \u003cp\u003e15.4 Joint modeling of longitudinal and survival responses 424\u003c\/p\u003e \u003cp\u003e15.4.1 Introduction 424\u003c\/p\u003e \u003cp\u003e15.4.2 An example 425\u003c\/p\u003e \u003cp\u003e15.5 Closing remarks 429\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Spatial applications: Disease mapping and image analysis 430\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 430\u003c\/p\u003e \u003cp\u003e16.2 Disease mapping 430\u003c\/p\u003e \u003cp\u003e16.2.1 Some general spatial epidemiological issues 431\u003c\/p\u003e \u003cp\u003e16.2.2 Some spatial statistical issues 433\u003c\/p\u003e \u003cp\u003e16.2.3 Count data models 433\u003c\/p\u003e \u003cp\u003e16.2.4 A special application area: Disease mapping\/risk estimation 434\u003c\/p\u003e \u003cp\u003e16.2.5 A special application area: Disease clustering 438\u003c\/p\u003e \u003cp\u003e16.2.6 A special application area: Ecological analysis 443\u003c\/p\u003e \u003cp\u003e16.3 Image analysis 444\u003c\/p\u003e \u003cp\u003e16.3.1 fMRI modeling 446\u003c\/p\u003e \u003cp\u003e16.3.2 A note on software 455\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Final chapter 456\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17.1 What this book covered 456\u003c\/p\u003e \u003cp\u003e17.2 Additional Bayesian developments 456\u003c\/p\u003e \u003cp\u003e17.2.1 Medical decision making 456\u003c\/p\u003e \u003cp\u003e17.2.2 Clinical trials 457\u003c\/p\u003e \u003cp\u003e17.2.3 Bayesian networks 457\u003c\/p\u003e \u003cp\u003e17.2.4 Bioinformatics 458\u003c\/p\u003e \u003cp\u003e17.2.5 Missing data 458\u003c\/p\u003e \u003cp\u003e17.2.6 Mixture models 458\u003c\/p\u003e \u003cp\u003e17.2.7 Nonparametric Bayesian methods 459\u003c\/p\u003e \u003cp\u003e17.3 Alternative reading 459\u003c\/p\u003e \u003cp\u003eAppendix: Distributions 460\u003c\/p\u003e \u003cp\u003eA.1 Introduction 460\u003c\/p\u003e \u003cp\u003eA.2 Continuous univariate distributions 461\u003c\/p\u003e \u003cp\u003eA.3 Discrete univariate distributions 477\u003c\/p\u003e \u003cp\u003eA.4 Multivariate distributions 481\u003c\/p\u003e \u003cp\u003eReferences 484\u003c\/p\u003e \u003cp\u003eIndex 509\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48864621232471,"sku":"9780470018231","price":53.15,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470018231.jpg?v=1722272766"},{"product_id":"medical-statistics-at-a-glance-workbook-9780470658482","title":"Medical Statistics at a Glance Workbook","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eDesigned to support the best-selling third edition of Medical Statistics at a Glance, this comprehensive workbook contains a variety of self-assessment methods allowing readers to test their statistical knowledge, put it into practice, and apply it to a medical context and when reading published literature.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eGreat workbook that compliments the respective textbook. Excercises are practical, short to the point. Good book of helping to understand the underlying concepts. (\u003cb\u003eAnthony Murray\u003c\/b\u003e, Faculty of Health \u0026amp; Science, University of Cumbria)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eIntroduction 6\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: Multiple-choice questions 8\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHandling data 8\u003c\/p\u003e \u003cp\u003eSampling and estimation 10\u003c\/p\u003e \u003cp\u003eStudy design 11\u003c\/p\u003e \u003cp\u003eHypothesis testing 13\u003c\/p\u003e \u003cp\u003eBasic techniques for analysing data 13\u003c\/p\u003e \u003cp\u003eAdditional techniques 20\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: Structured questions 24\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Critical appraisal 44\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRandomised controlled trial: template 44\u003c\/p\u003e \u003cp\u003eRandomised controlled trial: Paper 1 46\u003c\/p\u003e \u003cp\u003eObservational study: template 51\u003c\/p\u003e \u003cp\u003eObservational study: Paper 2 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: Data analysis 61\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDataset 1 analysed by Stata v11 (StataCorp LP, Texas, USA) 61\u003c\/p\u003e \u003cp\u003eDataset 2 analysed using IBM SPSS Statistics v20 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: Solutions 76\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSolutions to multiple-choice questions 76\u003c\/p\u003e \u003cp\u003eModel answers for structured questions 93\u003c\/p\u003e \u003cp\u003eRandomised controlled trial: critical appraisal of Paper 1 109\u003c\/p\u003e \u003cp\u003eObservational study: critical appraisal of Paper 2 113\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendices 117\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAppendix I: list of multiple-choice questions with relevant chapter numbers from Medical Statistics at a Glance (3rd edn) and associated topics 117\u003c\/p\u003e \u003cp\u003eAppendix II: list of structured questions with relevant chapter numbers from Medical Statistics at a Glance (3rd edn) and associated topics 119\u003c\/p\u003e \u003cp\u003eAppendix III: chapter numbers from Medical Statistics at a Glance (3rd edn) with relevant multiple-choice questions and structured questions 120\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":48864635617623,"sku":"9780470658482","price":20.85,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470658482.jpg?v=1722272830"},{"product_id":"infections-and-inequalities-9780520229136","title":"Infections and Inequalities","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eChallenging the accepted methodologies of epidemiology and international health, this book points out that most explanatory strategies, from 'cost-effectiveness' to patient 'noncompliance,' inevitably lead to blaming the victims.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"The only things that distinguish Farmer's account from a Dostoevskian novel is a meed of hard, effective science and a depressingly familiar story of the powerfully malignant of racism.... It is hard to think of more compelling examples to underpin his arguments. It makes the book and its message accessible to the general reader and forcefully reminds doctors, nurses, scientists, sociologists, economists and aid workers of their unfinished business.... But the main lessons he draws are for us all. We must do all we can to diminish social inequality.\" - Hugh Pennington, Times Higher Education Supplement \"A strangely uplifting read. Infections and Inequalities is a powerful and rigorously argued critique of economic and health care inequality.\" - Phil Whitaker, The Guardian (UK) \"Bolstered by thorough knowledge of the countries in which he practiced, relevant and cogent case histories, and a caring but disciplined attitude, Farmer powerfully argues for substantial changes in epidemiological theory and practice. He raises thought-provoking and necessary questions, and he provides answers that, if often unsettling, are pertinent and capable of being put to use by individuals and governments truly interested in solving, not sidestepping, life-threatening situations.\" - William Beatty, Booklist\"\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface to the Paperback Edition\u003cbr\u003e Acknowledgments\u003cbr\u003e Introduction\u003cbr\u003e\u003cbr\u003e 1. The Vitality of Practice: On Personal Trajectories\u003cbr\u003e 2. Rethinking \"Emerging Infectious Diseases\"\u003cbr\u003e 3. Invisible Women: Class, Gender, and HIV\u003cbr\u003e 4. The Exotic and the Mundane:\u003cbr\u003e Human Immunodeficiency Vrrus in the Caribbean\u003cbr\u003e 5. Culture, Poverty, and ffiV Transmission:\u003cbr\u003e The Case of Rural Haiti\u003cbr\u003e Miracles and Misery: An Ethnographic Interlude\u003cbr\u003e 6. Sending Sickness:\u003cbr\u003e Sorcery, Politics, and Changing Concepts\u003cbr\u003e of AIDS in Rural Haiti\u003cbr\u003e 7. The Consumption of the Poor:\u003cbr\u003e Tuberculosis .in the Late Twentieth Century\u003cbr\u003e 8. Optimism and Pessimism in Tuberculosis Control:\u003cbr\u003e Lessons from Rural Haiti\u003cbr\u003e 9. Immodest Claims of Causality:\u003cbr\u003e Social Scientists and the \"New\" Tuberculosis\u003cbr\u003e 10. The Persistent Plagues:\u003cbr\u003e Biological Expressions of Social Inequalities\u003cbr\u003e\u003cbr\u003e Notes\u003cbr\u003e References\u003cbr\u003e Index","brand":"University of California Press","offers":[{"title":"Default Title","offer_id":48864846709079,"sku":"9780520229136","price":22.5,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780520229136.jpg?v=1722273230"},{"product_id":"house-on-fire-9780520274471","title":"House on Fire","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eTells how smallpox, a disease that killed, blinded, and scarred millions over centuries of human history, was completely eradicated in a spectacular triumph of medicine and public health. This title details the remarkable program that involved people from countries around the world in pursuit of a single objective - eliminating smallpox.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"Dr. Foege's book ... remind[s] us how fragile life looks.\" New York Times \"Bounces the reader along with him in his jeep, on motorbikes over rugged terrain and on bustling trains... (And) shows what can be accomplished when governments and thousands of health workers focus on a single objective. \" Wall Street Journal \"[Foege] writes a mixture of memoir, dry public health guide and riveting tale of an all-consuming mission.\" -- Tiffany O'Callaghan New Scientist \"A readable and thorough account by a key player in this outstanding victory for public health.\" Library Journal \"A reminder of the importance of preventive medicine.\" Jama \"A great, quick, and intensely personal read about the inside story of Foege's revolutionary idea and powerful actions... Foege was wise before his time.\" Medpage Today \"Demonstrate[s] the enormous benefit that can accrue to mankind when a determined and ambitious band of individuals come together.\" The Lancet \"Gives an intimate sense of what it is like to work on the ground in some of the world's most impoverished countries -- and tells what it is like to contribute to programs that really do change the world.\" Scienceblogs.com\/The Guardian \"Inspiring... A fascinating human interest account that is expertly merged with scientific facts.\" -- Pascal James Imperato Jrnl Of Community Health \"A fascinating account\" The Bulletin Of The Royal College Of Pathologists\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Illustrations Foreword by Carmen Hooker Odom and Samuel L. Milbank Foreword by David J. Sencer Preface  Part One. Africa: Identifying the Key Strategy 1. A Loathsome Disease 2. A Succession of Mentors 3. Practicing Public Health in Nigeria 4. Fire Line around a Virus 5. Extinguishing Smallpox in a Time of War  Part Two. India: Meeting the Challenge of Eradication 6. Under the Rule of Variola 7. Unwarranted Optimism 8. A Gorgeous Coalition 9. Rising Numbers, Refining Strategy 10. Water on a Burning House 11. Smallpox Zero  Conclusion Postscript Appendix: A Plan in the Event of Smallpox Bioterrorism Notes Glossary Index","brand":"University of California Press","offers":[{"title":"Default Title","offer_id":48864882524503,"sku":"9780520274471","price":18.9,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780520274471.jpg?v=1722273257"},{"product_id":"interpretation-and-uses-of-medical-statistics-9780632047635","title":"Interpretation and Uses of Medical Statistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIn 1969 the first edition of this book introduced the concepts of statistics and their medical application to readers with no formal training in this area. While retaining this basic aim, the authors have expanded the coverage in each subsequent edition to keep pace with the increasing use and sophistication of statistics in medical research.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"Medical Uses of Statistics, 3rd Edition\" presents the concepts of medical statistics across a broad range of topics with a practical perspective, a moderate level of detail, and a minimal number of formulae . . . The text is clearly written in a consistent style, as illustrated by these excerpts.\" (Journal of Clinical Research Best Practices, 8 August 2011)  \u003cp\u003e...the book can be warmly recommended as a textbook and reference for undergraduate medical students and health professionals.\"  Statistical Methods in Medical Research (on the fourth edition)\u003c\/p\u003e \u003cp\u003e\"It should prove useful for both undergraduate medical and paramedical students, and for postgraduate researchers and clinicians who wish to have a greater understanding of medical statistics or to analyse their own data.\"  Modern Medicine of Australia (on the fourth edition)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Describing Data - A Single Variable. \u003cp\u003e2. Probability, Populations and Samples.\u003c\/p\u003e \u003cp\u003e3. Associations: Chance, Confounded or Causal?.\u003c\/p\u003e \u003cp\u003e4. Confidence intervals: General principles; Proportions, Means, Medians, Counts and Rates.\u003c\/p\u003e \u003cp\u003e5. Hypothesis Testing: General Principles and One-sample Tests for Means, Proportions, Counts and Rates.\u003c\/p\u003e \u003cp\u003e6. Epidemiological and Clinical Research Methods.\u003c\/p\u003e \u003cp\u003e7. Confidence intervals and Hypothesis Tests: Two-group Comparisons.\u003c\/p\u003e \u003cp\u003e8. Sample Size Determination.\u003c\/p\u003e \u003cp\u003e9. Comparison of More than Two Independent Groups.\u003c\/p\u003e \u003cp\u003e10. Associations between Two Quantitative Variables: Regression and Correlation.\u003c\/p\u003e \u003cp\u003e11. Multivariate Analysis and the Control of Confounding!.\u003c\/p\u003e \u003cp\u003e12. Bias and Measurement Error.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eAppendix A Computational Shortcuts.\u003c\/p\u003e \u003cp\u003eAppendix B Statistical Tables.\u003c\/p\u003e \u003cp\u003eAppendix C A \"Cookbook\" of Hypothesis Tests and Confidence Intervals.\u003c\/p\u003e \u003cp\u003eAppendix D World Medical Association Declaration of Helsinki\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":48865459339607,"sku":"9780632047635","price":97.16,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780632047635.jpg?v=1722274061"},{"product_id":"essential-concepts-in-clinical-research-9780702073946","title":"Essential Concepts in Clinical Research","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eWhen you read that the authors of a book were proud to have \"escaped the 1970s without owning a leisure suit,\" you just know it's going to be good. Clearly, such authors have a different point of view-and a great sense of humor. Essential Concepts in Clinical Research is an accurate title; the book is a pragmatic guide to understanding and evaluating clinical research, and it is excellent. It is easy to read, contains a surprising amount of information for its size, and is well referenced. In addition to explaining the key points of epidemiological and clinical research designs, the book has lots of examples of good practices and bad mistakes, as well as several helpful flowcharts and illustrations. The authors write with humor (they somehow weave ancient Roman toilets and astrology into the mix) and with a great deal of authority. If you need to understand the clinical literature, this is probably the single best guide you can get.    Tom Lang, Tom Lang Communications and Training International   In this text physicians and allied health professionals will find a concise and insightful guide to the design and implementation of clinical research. Clearly written in short easy-to-digest chapters this text differs from other similar publications by providing practical clinical examples from the medical literature that highlight the concepts being discussed. Physicians, pharmacists and other allied health professions will find the insights offered by these authors to be invaluable in interpreting medical literature and established researchers will better understand how to optimize their conduct and interpretation of clinical research.   Robert Reid, Journal of Obstetrics \u0026amp; Gynecology Canada, 2019\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eIntroduction   1. An overview of clinical research: the lay of the land    Observational studies   2. Descriptive studies: what they can and cannot do   3. Bias and causal associations in observational research   4. Cohort studies: marching towards outcomes   5. Case-control studies: research in reverse   6. Finding controls for case-control studies: compared to what?   7. Limitations of observational epidemiology     Screening tests  8. Uses and abuses of screening tests   9. Refining clinical diagnosis with likelihood ratios    Randomized controlled trials  10. Boosting participant recruitment in trials   11. Sample size calculations in randomized trials: mandatory and mystical   12. Generation of allocation sequences in randomized trials: chance not choice   13. Generation of allocation sequences in non-double-blinded randomized trials: guarding against guessing   14. Allocation concealment in randomized trials: defending against deciphering   15. Exclusions and losses in randomized trials: sample size slippages   16. Blinding in randomized trials: hiding who got what   17. Implementing treatment blinding in randomized trials   18. Surrogate endpoints and composite outcomes: shortcuts to unknown destinations   19. Multiplicity in randomized trials I: endpoints and treatments   20. Multiplicity in randomized trials II: subgroup and interim analyses   21. Conducting randomized trials as part of a prospective meta-analysis   Publishing   22. Reporting studies in medical journals: CONSORT and other guidelines","brand":"Elsevier Health Sciences","offers":[{"title":"Default Title","offer_id":48865574453591,"sku":"9780702073946","price":35.14,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780702073946.jpg?v=1722274571"},{"product_id":"pharmaceutical-statistics-9780853694250","title":"Pharmaceutical Statistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten specifically for pharmacy students, this book explains basic statistics. It contains chapters on basic concepts such as types of data, graphical representation of data, distribution and standard deviation. More advanced statistical techniques, such as ANOVA, are also discussed.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e'This book is a welcome addition to the Pharmacy library...an undoubted strength of the book is its clarity in presentation...the book is highly recommended to any person interested in quantitative aspects of pharmacy...' Prof. Mike Roberts, the Department of Medicine, Department of Practice and Policy, Princess Alexandra Hospital, The University of Queensland, Australia, Journal of Pharmacy and Pharmacology, 1 May 2003\u003c\/p\u003e -- Mike Roberts * Journal of Pharmacy and Pharmacology *\u003cbr\u003e\u003cp\u003e'Pharmaceutical Statistics is well thought out and well written, with a good layout that does not get bogged down with overly complex explanations.' Henry Skupek, Program Support Coordinator, Australian College of Pharmacy Practice, Canberra, Australian Pharmacist, 1 Feb 2003\u003c\/p\u003e -- Henry Skupek * Australian Pharmacist *\u003cbr\u003e\u003cp\u003e'...the book is a useful addition to the range of books available on pharmaceutical statistics.' Alain Li Wan Po, The Pharmaceutical Journal, 7 June 2003\u003c\/p\u003e -- Alain Li Wan Po * The Pharmaceutical Journal *","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866059059543,"sku":"9780853694250","price":31.35,"currency_code":"GBP","in_stock":true}]},{"product_id":"introduction-to-pharmaceutical-calculations-9780857111685","title":"Introduction to Pharmaceutical Calculations","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIntroduction to Pharmaceutical Calculations is an essential study aid for pharmacy students. The book contains worked examples and sample questions and answers.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1 Introduction; 2 Rational Numbers; 3 Systems of Units; 4 Concentrations; 5 Dilutions; 6 Formulations; 7 Calculation of Doses; 8 Doses in Children; 9 Density, Displacement Volumes and Displacement Values; 10 Calculations Involving Molecular Weights; 11 Parenteral Solutions and Isotonicity; 12 Accuracy of Measurement; 13 Calculations Involving Information Retrieval.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068726103,"sku":"9780857111685","price":31.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857111685.jpg?v=1722276888"},{"product_id":"essential-medical-statistics-9780865428713","title":"Essential Medical Statistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eBlackwell Publishing is delighted to announce that this book has been Highly Commended in the 2004 BMA Medical Book Competition. Here is the judges' summary of this book:       \"This is a technical book on a technical subject but presented in a delightful way.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"This book is the statistics book of choice for anyone wanting a proper appreciation of the use and application of statistics in health care. I highly recommend this book.\" (Journal of Renal Nursing, 6 November 2011)  \u003cp\u003ethe breadth of coverage of the book is excellent ... a rather different approach to teaching medical statistics.\"\u003cbr\u003e Statistics in Medicine\u003c\/p\u003e \u003cp\u003e\"The most readable book that I have yet discovered in the topic\"\u003cbr\u003e Community Health Studies\u003c\/p\u003e \u003cp\u003e\"This book is statistically correct. That is enough to distinguish it from most of its competitors.\"\u003cbr\u003e British Medical Journal\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003ePublished Reviews of the 2th Edition\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"One word which definitely describes this book is \"comprehensive\". Anything you ever wanted to know about medical statistics is covered in immense detail.\"\u003c\/p\u003e \u003cp\u003e\u003ci\u003e4th Year Medical Student\u003cbr\u003e \u003c\/i\u003e\u003ci\u003eLiverpool Medical School\u003cbr\u003e \u003c\/i\u003e\u003ci\u003eSphincter,\u003c\/i\u003e \u003ci\u003eDecember 2003\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\"This is a comprehensive book that includes an impressive range of topics often omitted from books aimed at non-statisticians.\u003c\/p\u003e \u003cp\u003e...a resource that makes it easy for a beginner to comprehend a wide range of statistical concepts and tools. \u003ci\u003eEssential Medical Statistics\u003c\/i\u003e fills an important niche by providing practical information on a comprehensive scope of modern statistical methods and, at the same time, communicating on the same wavelengths as physicians and other nonstatisticians.\"\u003c\/p\u003e \u003cp\u003e\u003ci\u003eTeaching of Statistics in the Health Sciences, Section of the American Statistical Association, Spring 2004\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\"The book is laid out in a logical fashion and includes all of the tables you need to find p-values once you have performed a test. It covers simple statistical methods, such as how to calculate the mean and standard deviation, progressing to linear and multiple regression, Poisson regression and measures of impact and association.\u003c\/p\u003e \u003cp\u003e...I would recommend using it to anyone who is still struggling with statistics.\"\u003c\/p\u003e \u003cp\u003e\u003ci\u003eNorth Wing, Sheffield Medics Magazine, Winter 2004\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\"The book is generally well laid out, the indexing is well structured and a comprehensive bibliography is provided. The topics are easy to locate and include practical examples. These attributes make it a useful text for both consulting and teaching purposes.\"\u003cbr\u003e \u003ci\u003eStatistics in Medicine, Vol 24, Number 5, March 2005\u003c\/i\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart A. Basics. \u003cp\u003e1. Using this book.\u003c\/p\u003e \u003cp\u003e2. Defining the data.\u003c\/p\u003e \u003cp\u003e3. Displaying the data.\u003c\/p\u003e \u003cp\u003ePart B. Analysis of numerical outcomes.\u003c\/p\u003e \u003cp\u003e4. Means, Standard Deviations and Standard Errors.\u003c\/p\u003e \u003cp\u003e5. The Normal Distribution.\u003c\/p\u003e \u003cp\u003e6. Confidence Interval for a Mean.\u003c\/p\u003e \u003cp\u003e7. Comparison of two means: confidence intervals, hypothesis tests and P-values.\u003c\/p\u003e \u003cp\u003e8. Using P-values and confidence intervals to interpret the results of statistical analyses.\u003c\/p\u003e \u003cp\u003e9. Comparison of means from several groups: analysis of variance.\u003c\/p\u003e \u003cp\u003e10. Linear Regression and Correlation.\u003c\/p\u003e \u003cp\u003e11. Multiple Regression.\u003c\/p\u003e \u003cp\u003e12. Goodness of fit and regression diagnostics.\u003c\/p\u003e \u003cp\u003e13. Transformations.\u003c\/p\u003e \u003cp\u003ePart C. Analysis of binary outcomes.\u003c\/p\u003e \u003cp\u003e14. Probability, risks and odds (of disease).\u003c\/p\u003e \u003cp\u003e15. Proportions and the binomial distribution.\u003c\/p\u003e \u003cp\u003e16. Comparing two proportions.\u003c\/p\u003e \u003cp\u003e17. Chi-squared tests for 2 × 2 and larger contingency tables.\u003c\/p\u003e \u003cp\u003e18. Controlling for confounding: stratification.\u003c\/p\u003e \u003cp\u003e19. Logistic regression: comparing two or more exposure groups.\u003c\/p\u003e \u003cp\u003e20. Logisitic regression: controlling for confounding and other extensions.\u003c\/p\u003e \u003cp\u003e21. Matched studies.\u003c\/p\u003e \u003cp\u003ePart D. Longitudinal studies: Analysis of rates and survival times.\u003c\/p\u003e \u003cp\u003e22. Longitudinal studies, rates and the Poisson distribution.\u003c\/p\u003e \u003cp\u003e23. Comparing rates.\u003c\/p\u003e \u003cp\u003e24. Poisson regression.\u003c\/p\u003e \u003cp\u003e25. Standardisation.\u003c\/p\u003e \u003cp\u003e26. Survival analysis: displaying and comparing survival patterns.\u003c\/p\u003e \u003cp\u003e27. Regression analysis of survival data.\u003c\/p\u003e \u003cp\u003ePart E. Statistical modelling.\u003c\/p\u003e \u003cp\u003e28. Likelihood.\u003c\/p\u003e \u003cp\u003e29. Regression modelling.\u003c\/p\u003e \u003cp\u003e30. Relaxing model assumptions.\u003c\/p\u003e \u003cp\u003e31. Analysis of clustered data.\u003c\/p\u003e \u003cp\u003e32. Systematic reviews and meta-analysis.\u003c\/p\u003e \u003cp\u003e33. Bayesian statistics.\u003c\/p\u003e \u003cp\u003ePart F. Study design, analysis and interpretation.\u003c\/p\u003e \u003cp\u003e34. Linking analysis to study design: summary of methods.\u003c\/p\u003e \u003cp\u003e35. Calculation of Required Sample Size.\u003c\/p\u003e \u003cp\u003e36. Measurement error: assessment and implications.\u003c\/p\u003e \u003cp\u003e37. Measures of association and impact.\u003c\/p\u003e \u003cp\u003e38. Strategies for analysis.\u003c\/p\u003e \u003cp\u003eAPPENDIX: Statistical Tables.\u003c\/p\u003e \u003cp\u003eBibliography\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":48866111848791,"sku":"9780865428713","price":44.6,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780865428713.jpg?v=1722277094"},{"product_id":"methods-and-applications-of-statistics-in-clinical-trials-volume-2-9781118304761","title":"Methods and Applications of Statistics in","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003ci\u003eMethods and Applications of Statistics in Clinical Trials, Volume 2: Planning, Analysis, and Inferential Methods\u003c\/i\u003e includes updates of established literature from the Wiley Encyclopedia of Clinical Trials as well as original material based on the latest developments in clinical trials. Prepared by a leading expert, the second volume includes numerous contributions from current prominent experts in the field of medical research. In addition, the volume features:\u003c\/p\u003e \u003cp\u003e Multiple new articles exploring emerging topics, such as evaluation methods with threshold, empirical likelihood methods, nonparametric ROC analysis, over- and under-dispersed models, and multi-armed bandit problems\u003c\/p\u003e \u003cp\u003e Up-to-date research on the Cox proportional hazard model, frailty models, trial reports, intrarater reliability, conditional power, and the kappa index\u003c\/p\u003e \u003cp\u003e Key qualitative issues including cost-effectiveness analysis, publication bias, and regulatory issues, which are crucial to the planni\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e“This book provides a good overview on most relevant topics for clinical trials.”  (\u003ci\u003eBiometrical Journal\u003c\/i\u003e, 1 October 2015)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eContributors xix \u003cp\u003ePreface xxiii\u003c\/p\u003e \u003cp\u003e1 Analysis of Over- and Underdispersed Data 1\u003c\/p\u003e \u003cp\u003e2 Analysis of Variance (ANOVA) 10\u003c\/p\u003e \u003cp\u003e3 Assessment of Health-Related Quality of Life 26\u003c\/p\u003e \u003cp\u003e4 Bandit Processes and Response-Adaptive Clinical Trials: The Art of Exploration Versus Exploitation 40\u003c\/p\u003e \u003cp\u003e5 Bayesian Dose-Finding Designs in Healthy Volunteers 51\u003c\/p\u003e \u003cp\u003e6 Bootstrap 62\u003c\/p\u003e \u003cp\u003e7 Conditional Power in Clinical Trial Monitoring 102\u003c\/p\u003e \u003cp\u003e8 Cost-Effectiveness Analysis 111\u003c\/p\u003e \u003cp\u003e9 Cox-Type Proportional Hazards Models 126\u003c\/p\u003e \u003cp\u003e10 Empirical Likelihood Methods in Clinical Experiments 146\u003c\/p\u003e \u003cp\u003e11 Frailty Models 166\u003c\/p\u003e \u003cp\u003e12 Futility Analysis 174\u003c\/p\u003e \u003cp\u003e13 Imaging Science in Medicine I: Overview 187\u003c\/p\u003e \u003cp\u003e14 Imaging Science in Medicine, II: Basics of X-Ray Imaging 213\u003c\/p\u003e \u003cp\u003e15 Imaging Science in Medicine, III: Digital (21st Century) X-Ray Imaging 264\u003c\/p\u003e \u003cp\u003e16 Intention-to-Treat Analysis 313\u003c\/p\u003e \u003cp\u003e17 Interim Analyses 323\u003c\/p\u003e \u003cp\u003e18 Interrater Reliability 334\u003c\/p\u003e \u003cp\u003e19 Intrarater Reliability 340\u003c\/p\u003e \u003cp\u003e20 Kaplan-Meier Plot 357\u003c\/p\u003e \u003cp\u003e21 Logistic Regression 365\u003c\/p\u003e \u003cp\u003e22 Metadata 380\u003c\/p\u003e \u003cp\u003e23 Microarray 392\u003c\/p\u003e \u003cp\u003e24 Multi-Armed Bandits, Gittins Index, and Its Calculation 416\u003c\/p\u003e \u003cp\u003e25 Multiple Comparisons 436\u003c\/p\u003e \u003cp\u003e26 Multiple Evaluators 446\u003c\/p\u003e \u003cp\u003e27 Noncompartmental Analysis 457\u003c\/p\u003e \u003cp\u003e28 Nonparametric ROC Analysis for Diagnostic Trials 483\u003c\/p\u003e \u003cp\u003e29 Optimal Biological Dose for Molecularly Targeted Therapies 496\u003c\/p\u003e \u003cp\u003e30 Over- and Underdispersion Models 506\u003c\/p\u003e \u003cp\u003e31 Permutation Tests in Clinical Trials 527\u003c\/p\u003e \u003cp\u003e32 Pharmacoepidemiology, Overview 536\u003c\/p\u003e \u003cp\u003e33 Population Pharmacokinetic and Pharmacodynamic Methods 551\u003c\/p\u003e \u003cp\u003e34 Proportions: Inferences and Comparisons 570\u003c\/p\u003e \u003cp\u003e35 Publication Bias 595\u003c\/p\u003e \u003cp\u003e36 Quality of Life 608\u003c\/p\u003e \u003cp\u003e37 Relative Risk Modeing 622\u003c\/p\u003e \u003cp\u003e38 Sample Size Considerations for Morbidity\/Mortality Trials 633\u003c\/p\u003e \u003cp\u003e39 Sample Size for Comparing Means 642\u003c\/p\u003e \u003cp\u003e40 Sample Size for Comparing Proportions 653\u003c\/p\u003e \u003cp\u003e41 Sample Size for Comparing Time-to-Event Data 664\u003c\/p\u003e \u003cp\u003e42 Sample Size for Comparing Variabilities 672\u003c\/p\u003e \u003cp\u003e43 Screening, Models of 689\u003c\/p\u003e \u003cp\u003e44 Screening Trials 721\u003c\/p\u003e \u003cp\u003e45 Secondary Efficacy End Points 731\u003c\/p\u003e \u003cp\u003e46 Sensitivity, Specificity, and Receiver Operator Characteristic (ROC) Methods 740\u003c\/p\u003e \u003cp\u003e47 Software for Genetics\/Genomics 752\u003c\/p\u003e \u003cp\u003e48 Stability Study Designs 778\u003c\/p\u003e \u003cp\u003e49 Subgroup Analysis 793\u003c\/p\u003e \u003cp\u003e50 Survival Analysis, Overview 802\u003c\/p\u003e \u003cp\u003e51 The FDA and Regulatory Issues 815\u003c\/p\u003e \u003cp\u003e52 The Kappa Index 836\u003c\/p\u003e \u003cp\u003e53 Treatment Interruption 846\u003c\/p\u003e \u003cp\u003e54 Trial Reports: Improving Reporting, Minimizing Bias, and Producing Better Evidence-Based Practice 860\u003c\/p\u003e \u003cp\u003e55 U.S. Department of Veterans Affairs Cooperative Studies Program 876\u003c\/p\u003e \u003cp\u003e56 Women's Health Initiative: Statistical Aspects and Selected Early Results 901\u003c\/p\u003e \u003cp\u003e57 World Health Organization (WHO): Global Health Situation 914\u003c\/p\u003e \u003cp\u003eIndex 925\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48866368389463,"sku":"9781118304761","price":157.45,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118304761.jpg?v=1722278315"},{"product_id":"introduction-to-metaanalysis-9781119558354","title":"Introduction to MetaAnalysis","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Tables xv\u003c\/p\u003e \u003cp\u003eList of Figures xix\u003c\/p\u003e \u003cp\u003eAcknowledgements xxv\u003c\/p\u003e \u003cp\u003ePreface xxvii\u003c\/p\u003e \u003cp\u003ePreface to the Second Edition xxxv\u003c\/p\u003e \u003cp\u003eWebsite xxxvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: Introduction\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 How a Meta-Analysis Works 3\u003c\/p\u003e \u003cp\u003e2 Why Perform a Meta-Analysis 9\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: Effect Size and Precision\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3 Overview 17\u003c\/p\u003e \u003cp\u003e4 Effect Sizes Based On Means 21\u003c\/p\u003e \u003cp\u003e5 Effect Sizes Based On Binary Data (2 × 2 Tables) 33\u003c\/p\u003e \u003cp\u003e6 Effect Sizes Based On Correlations 39\u003c\/p\u003e \u003cp\u003e7 Converting Among Effect Sizes 43\u003c\/p\u003e \u003cp\u003e8 Factors That Affect Precision 49\u003c\/p\u003e \u003cp\u003e9 Concluding Remarks 55\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Fixed-Effect Versus Random-Effects Models\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Overview 59\u003c\/p\u003e \u003cp\u003e11 Fixed-Effect Model 61\u003c\/p\u003e \u003cp\u003e12 Random-Effects Model 65\u003c\/p\u003e \u003cp\u003e13 Fixed-Effect Versus Random-Effects Models 71\u003c\/p\u003e \u003cp\u003e14 Worked Examples (Part 1) 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: Heterogeneity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15 Overview 97\u003c\/p\u003e \u003cp\u003e16 Identifying and Quantifying Heterogeneity 99\u003c\/p\u003e \u003cp\u003e17 Prediction Intervals 119\u003c\/p\u003e \u003cp\u003e18 Worked Examples (Part 2) 127\u003c\/p\u003e \u003cp\u003e19 An Intuitive Look At Heterogeneity 139\u003c\/p\u003e \u003cp\u003e20 Classifying Heterogeneity As Low, Moderate, Or High 155\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: Explaining Heterogeneity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21 Subgroup Analyses 161\u003c\/p\u003e \u003cp\u003e22 Meta-Regression 197\u003c\/p\u003e \u003cp\u003e23 Notes On Subgroup Analyses and Meta-Regression 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6: Putting It All In Context\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Looking At the Whole Picture 223\u003c\/p\u003e \u003cp\u003e25 Limitations of the Random-Effects Model 233\u003c\/p\u003e \u003cp\u003e26 Knapp–Hartung Adjustment 243\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7: Complex Data Structures\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Overview 253\u003c\/p\u003e \u003cp\u003e28 Independent Subgroups Within a Study 255\u003c\/p\u003e \u003cp\u003e29 Multiple Outcomes or Time-Points Within A Study 263\u003c\/p\u003e \u003cp\u003e30 Multiple Comparisons Within a Study 277\u003c\/p\u003e \u003cp\u003e31 Notes On Complex Data Structures 281\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8: Other Issues\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e32 Overview 287\u003c\/p\u003e \u003cp\u003e33 Vote Counting – A New Name For An Old Problem 289\u003c\/p\u003e \u003cp\u003e34 Power Analysis For Meta-Analysis 295\u003c\/p\u003e \u003cp\u003e35 Publication Bias 313\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9: Issues Related To Effect Size\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e36 Overview 335\u003c\/p\u003e \u003cp\u003e37 Effect Sizes Rather Than P-Values 337\u003c\/p\u003e \u003cp\u003e38 Simpson’s Paradox 343\u003c\/p\u003e \u003cp\u003e39 Generality of the Basic Inverse-Variance Method 349\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 10: Further Methods\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e40 Overview 361\u003c\/p\u003e \u003cp\u003e41 Meta-Analysis Methods Based On Direction and P-Values 363\u003c\/p\u003e \u003cp\u003e42 Further Methods For Dichotomous Data 369\u003c\/p\u003e \u003cp\u003e43 Psychometric Meta-Analysis 377\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 11: Meta-Analysis In Context\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e44 Overview 391\u003c\/p\u003e \u003cp\u003e45 When Does It Make Sense To Perform a Meta-Analysis? 393\u003c\/p\u003e \u003cp\u003e46 Reporting The Results of a Meta-Analysis 401\u003c\/p\u003e \u003cp\u003e47 Cumulative Meta-Analysis 407\u003c\/p\u003e \u003cp\u003e48 Criticisms of Meta-Analysis 413\u003c\/p\u003e \u003cp\u003e49 Comprehensive Meta-Analysis Software 425\u003c\/p\u003e \u003cp\u003e50 How To Explain the Results of An Analysis 443\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 12: Resources\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e51 Software For Meta-Analysis 471\u003c\/p\u003e \u003cp\u003e52 Web Sites, Societies, Journals, and Books 473\u003c\/p\u003e \u003cp\u003eWeb sites 473\u003c\/p\u003e \u003cp\u003eProfessional societies 476\u003c\/p\u003e \u003cp\u003eJournals 476\u003c\/p\u003e \u003cp\u003eSpecial issues dedicated to meta-analysis 477\u003c\/p\u003e \u003cp\u003eBooks on systematic review methods and meta-analysis 477\u003c\/p\u003e \u003cp\u003eReferences 479\u003c\/p\u003e \u003cp\u003eIndex 491\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48866402795863,"sku":"9781119558354","price":58.85,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119558354.jpg?v=1722278475"},{"product_id":"the-analysis-of-biological-data-9781319325343","title":"The Analysis of Biological Data","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"Macmillan Learning","offers":[{"title":"Default Title","offer_id":48866557165911,"sku":"9781319325343","price":63.64,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781319325343.jpg?v=1722279209"},{"product_id":"vaccines-autoimmunity-and-the-changing-nature-of-childhood-illness-9781603587778","title":"Vaccines, Autoimmunity, and the Changing Nature","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cstrong\u003eOne doctor’s surprising answer to the epidemic of chronic disease and essential reading for everyone concerned with the health of the next generation\u003c\/strong\u003e\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003e..[T]he further we move away from nature the sicker we become, and it is our children who pay the heaviest price for what modern civilization is doing to our environment and our bodies. This book will make the reader think. I warmly recommend it! \u003c\/strong\u003eDr. Natasha Campbell-McBride, MD, author of \u003cem\u003eGut and Psychology Syndrome\u003c\/em\u003e\u003c\/p\u003e  \u003cp\u003eOver the past fifty years, rates of autoimmunity and chronic disease have exploded. While some attribute this rise to increased awareness and diagnosis, Thomas Cowan, MD, argues for a direct causal relationship to a corresponding increase in the number of vaccines children typically receive. \u003c\/p\u003e  \u003cp\u003eDr. Cowan looks at emerging evidence that certain childhood illnesses are actually protective of disease later in life; examines the role of fever, the gut and cellular fluid in immune health; argues that vaccination is an ineffective (and harmful) attempt to shortcut a complex immune response; and asserts that the medical establishment has engaged in an authoritarian argument that robs parents of informed consent. His ultimate question, from the point of view of a doctor who has decades of experience treating countless children is: What are we really doing to children when we vaccinate them?\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eDr. Cowan intelligently educates us on the complicated and beautiful workings of our immune system, clearly explains how and why its malfunction is harming us, and elucidates why our precious children are so vulnerable to these diseases. \u003c\/strong\u003eLindy Woodard, MD, Pediatric Alternatives\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“Dr. Tom Cowan has created an entertaining, compelling, and readily accessible book explaining the risks involved in today’s overaggressive vaccination campaign. I particularly appreciate his emphasis on the risks to autoimmune disease inherent in antibody induction through vaccines. This book is a great addition to the growing body of literature revealing why vaccination is not the best strategy for protection against infectious diseases.”\u003cstrong\u003e—Stephanie Seneff, senior research scientist, MIT Computer Science and Artificial Intelligence Laboratory\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“I would like to thank Dr. Tom Cowan for writing this book! Humanity seems to have forgotten that human body is part of nature; the further we move away from nature the sicker we become, and it is our children who pay the heaviest price for what modern civilization is doing to our environment and our bodies. This book will make the reader think. I warmly recommend it!”\u003cstrong\u003e—Dr. Natasha Campbell-McBride, MD, author of \u003cem\u003eGut and Psychology Syndrome\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“Dr. Cowan does a great job explaining in clear and common-sense terms that the practice and the rationale of vaccination is deeply flawed, and, astoundingly, is not evidence-based but rather fear-based. The vaccine paradigm is upheld by the consensus, but the consensus in not based on a free and unbiased reading of all the evidence, rather only on a small part of it, while much is ignored. Dr. Cowan contributes greatly to a much-needed correction of this misleading and misled consensus.”\u003cstrong\u003e—Philip Incao, MD, advisor, Physicians for Informed Consent\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“Tom Cowan’s \u003cem\u003eVaccines, Autoimmunity, and the Changing Nature of Childhood Illness\u003c\/em\u003e is both brilliant and beautifully simple. He shares facts not taught in medical school, that reflect ancient wisdom, common sense, and trust in the intelligence of life itself. Understanding the role of childhood illnesses such as chickenpox and measles is critical to our survival as a species. Tom does an outstanding job of connecting the dots and giving reason to what is often misunderstood!”\u003cstrong\u003e—Cilla Whatcott, producer of the film \u003cem\u003eReal Immunity\u003c\/em\u003e; author of \u003cem\u003eThere is a Choice\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“As a pediatrician for thirty-five years, I have seen the enormous rise in autoimmune diseases like asthma, allergies, eczema, and autism. We no longer need to scratch our heads wondering why, because the reasons are clear. In \u003cem\u003eVaccines, Autoimmunity, and the Changing Nature of Childhood Illness, \u003c\/em\u003eDr. Cowan intelligently educates us on the complicated and beautiful workings of our immune system, clearly explains how and why its malfunction is harming us, and elucidates why our precious children are so vulnerable to these diseases. Most importantly, perhaps, Dr. Cowan charts the clear, concise path to healing, offering a better, healthier life for us, our children, and the planet.”\u003cstrong\u003e—Lindy Woodard, MD, Pediatric Alternatives\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“We westerners must wake up to the fact that vaccination is driving our modern epidemics of autism, dementia, autoimmunity, and allergies. In \u003cem\u003eVaccines, Autoimmunity, and the Changing Nature of Childhood Illness\u003c\/em\u003e, Dr. Thomas Cowan whistle-blows on Big Pharma and the medical profession. Quite rightly, too. Human misery aside, these diseases are debilitatingly expensive. Autism usually results in care for life.\u003c\/p\u003e  \u003cp\u003e“The arguments Dr. Cowan makes are not only biologically plausible, but are based in good science. He states what, for many, is the obvious: we must learn to live within the laws of nature, not fight against them as if they were some evil force. Evolution has the answers! We have lived with microorganisms for millions of years, and many confer significant survival benefits. Cowan details this with devastating logic. Childhood infections such as chickenpox and measles are \u003cem\u003edesirable\u003c\/em\u003e; they program the immune system in such a way as to protect us from disease later in life.\u003c\/p\u003e  \u003cp\u003e“This book gives parents the intellectual ammunition they need to fight back against the pro-vaccine medical establishment. They clearly need such. I have seen parents driven by fear into vaccinating their children entirely against their parental instincts. By not vaccinating, Cowan shows us how children can be protected from allergy, autoimmunity, attention deficit\/hyperactivity disorder, asthma, and autism. This book is essential reading for all concerned with the health of the next generation.”\u003cstrong\u003e—Dr. Sarah Myhill, author of \u003cem\u003eSustainable Medicine\u003c\/em\u003e and \u003cem\u003eDiagnosis and Treatment of Chronic Fatigue Syndrome and Myalgic Encephalitis\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e“Thomas Cowan, MD, is a gifted physician and scientist. He is also a man of integrity who sticks his neck out for the truth. In addition he has the talent for making complex and urgent topics easy to read and understand for the intelligent layperson. He has accomplished this with his book, \u003cem\u003eHuman Heart, Cosmic Heart\u003c\/em\u003e, the best book out there on holistically healing cardiovascular diseases\u003cem\u003e. \u003c\/em\u003eNow he has done it again with \u003cem\u003eVaccines, Autoimmunity, and the Changing Nature of Childhood Illness\u003c\/em\u003e.\u003c\/p\u003e  \u003cp\u003e“Vaccination has been a controversial topic for decades with informed parents around the world having to struggle with regulatory authorities and doctors over the necessity and effectiveness of vaccination to prevent childhood diseases. Now Dr. Cowan comes out with a powerful book giving a clear scientific voice to the intuition of many parents regarding the dangers of vaccination. Tamper with our immune system through one-sided interventions, and pay a tragic price.\u003c\/p\u003e  \u003cp\u003e“This book is a global wake-up call to defend, against those who would destroy it, the awesome wisdom of the human body to wage its own battle against the myriad diseases that seek to overcome our internal defense system. This book will have a profound, beneficial impact on human health around the world in the years and decades to come. It is a courageous and pioneering work worthy of admiration and support.”\u003cstrong\u003e—Nicanor Perlas, recipient, Right Livelihood Award\u003c\/strong\u003e\u003c\/p\u003e","brand":"Chelsea Green Publishing Co","offers":[{"title":"Default Title","offer_id":48867712991575,"sku":"9781603587778","price":17.09,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781603587778.jpg?v=1722284605"},{"product_id":"getting-to-zero-a-doctor-and-a-diplomat-on-the-ebola-frontline-9781786992482","title":"Getting to Zero: A Doctor and a Diplomat on the","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIn 2014, a 28-year old British doctor found himself co-running the Ebola isolation unit in Sierra Leone’s main hospital after the doctor in charge had been killed by the virus. Completely overwhelmed and wrapped in stifling protective suits, he and his team took it in turns to provide care to patients while removing dead bodies from the ward. Against all odds he battled to keep the hospital open, as the queue of sick and dying patients grew every day.  Only a few miles down the road the Irish Ambassador and Head of Irish Aid worked relentlessly to rapidly scale up the international response. At a time when entire districts had been quarantined, she travelled around the country, and met with UN agencies, the President and senior ministers so as to be better placed in alerting the world to the catastrophe unfolding in front of her.  In this blow-by-blow account, Walsh and Johnson expose the often shocking shortcomings of the humanitarian response to the outbreak, both locally and internationally, and call our attention to the immense courage of those who put their lives on the line every day to contain the disease. Theirs is the definitive account of the fight against an epidemic that shook the world.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGetting to Zero\u003c\/i\u003e is a compelling read, full of compassion, grief, ingenuity and stories of courage and unstinting commitment of local nurses, cleaners and others who remain unsung heroes of Ebola. But it is also full of tales of denial, extraordinary lapses in leadership and awkward truths that will make uncomfortable reading for many, locally and internationally. * Guardian *\u003cbr\u003eWritten in an honest and engaging tone, their experience behind the scenes of the outbreak is illuminating and highlights important lessons for the management of future outbreaks, and the operational errors that increased the number of lives lost in the west African outbreak of 2014–16. * Lancet *\u003cbr\u003eHundreds of reports have been written on the 2014 epidemic – the most widespread Ebola outbreak since the virus was discovered – but none is nearly as insightful, compassionate or unsparing as this. * Irish Times *\u003cbr\u003eA brave, bold, yet humble account from the frontlines of the Ebola outbreak in Sierra Leone. This is vital reading to help us all do better next time. * David Miliband, President and CEO of the International Rescue Committee *\u003cbr\u003eCourage in extreme clinical danger, courage to challenge obstructive bureaucracy, courage to make tough decisions and the courage to endure. This is the courage that Sinead Walsh and Oliver Johnson displayed in Sierra Leone. Their compelling book is essential reading for all who care about global health. * Eldryd Parry, founder of the Tropical Health and Education Trust *\u003cbr\u003eA captivating and brutally honest account of the Ebola epidemic from two brave, committed individuals who unexpectedly found themselves at its epicentre. The authors pull no punches, and leave us asking: will these lessons be learned, or will the world once again forget and move on? * Jeremy Farrar, Director of the Wellcome Trust *\u003cbr\u003eThis powerful book asks important questions about aid and development and offers insights that everyone working in global health should absorb – as well as being a personal and very moving account of an epidemic that killed thousands. * Lord Nigel Crisp, Co-Chair of the All Party Parliamentary Group on Global Health *\u003cbr\u003eWalsh and Johnson represent the best of international intervention. This book reveals the complexities and level of cooperation that made “getting to zero” possible. Offers excellent insight into those trying times. * O.B. Sisay, Director of the Situation Room at the National Ebola Response Centre, Sierra Leone *\u003cbr\u003eAn extraordinary account from the thick of the battle against Ebola. This is history’s first draft, and a powerful example of persistent and pragmatic leadership. Mandatory reading for anyone concerned with global health in the broadest sense. * Paul Farmer, Harvard Medical School, and co-founder of Partners in Health *\u003cbr\u003eTakes us behind the scenes to the harrowing frontlines of the Ebola epidemic – highlighting a set of lessons that an inter-connected world would ignore at our peril. A compelling read. * Samantha Power, former US Ambassador to the UN *\u003cbr\u003eA detailed, up-close-and-personal perspective on the Ebola epidemic in Sierra Leone, important for all who want to understand what it is to confront a terrible health threat. * Tom Frieden, President and CEO of Resolve to Save Lives, and former Director of the Centers for Disease Control and Prevention *\u003cbr\u003eJohnson and Walsh provide a frank, beautifully written, and essential guide to the lessons learned from the heart of the outbreak. Their first-hand experiences in battling this terrible disease will take your breath away. A must read. * Tulip Mazumdar, Global Health Correspondent for BBC News *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eMaps    Preface     1. New Beginnings: Sierra Leone before the Outbreak of Ebola    2. A Dubious Start: Ebola in Guinea    3. Ebola Emerges in Sierra Leone    4. Kenema Explodes    5. Armageddon    6. The Long Wait for Action    7. The Response Kicks Off    8. The Response Bears Fruit    9. Getting to Zero    10. Conclusion    Afterword: If We Had to Do It All Again…","brand":"Bloomsbury Publishing PLC","offers":[{"title":"Default Title","offer_id":48868387717463,"sku":"9781786992482","price":15.19,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781786992482.jpg?v=1722287803"},{"product_id":"medical-statistics-made-easy-fourth-edition-9781911510635","title":"Medical Statistics Made Easy, fourth edition","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cstrong\u003eContains all you need to know to understand statistics in medicine.\u003cbr\u003e \u003cbr\u003e \u003cem\u003eMedical Statistics Made Easy\u003c\/em\u003e\u003c\/strong\u003e has been a perennial bestseller since the first edition was published (it is consistently a #1 bestseller in medical statistics\/biostatistics on Amazon).\u003cbr\u003e \u003cbr\u003e It is recommended and required worldwide on a variety of courses and programmes, from undergraduate medicine, through to professional medical qualifications.\u003cbr\u003e \u003cbr\u003e It is a \u003cstrong\u003ebook of key statistics principles \u003c\/strong\u003efor anyone studying or working in medicine and healthcare who needs a basic overview of the subject. It is \u003cstrong\u003eideal for non-statisticians\u003c\/strong\u003e who need to understand how statistics are used and applied in medicine and medical research.\u003cbr\u003e \u003cbr\u003e Using a consistent format, the authors describe the most common statistical methods in turn and then rate them on how difficult they are to understand and how common they are. The worked examples that demonstrate the statistical method in action include current articles from the medical literature and now feature a wider range of medical journals.\u003cbr\u003e \u003cbr\u003e This fourth edition continues with the same structure as the previous editions, with new sections on cut-off points and ROC curves, as well as a new chapter on choosing the right statistical test. It also features a completely revised and updated 'Statistics at work' section.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cstrong\u003e\u003cem\u003eFive-star reviews of the previous edition:\u003c\/em\u003e\u003c\/strong\u003e\u003cbr\u003e \u003cstrong\u003eWell balanced and sufficient for medical trainees and doctors\u003c\/strong\u003e \"Extremely easy to read and understand, just the right amount of info a doctor or a medical student needs to interpret a paper. Essential read if you have not done A-level mathematics.\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003ePerfect for AKT revision\u003c\/strong\u003e \"I was recommended this book for AKT revision. It has all the information needed and more... I found it easy to interpret and pitched at the right level even if you find medical statistics daunting.\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eUseful if reading lots of random medical papers\u003c\/strong\u003e \"Excellent for a medical writer who deals with lots of random stats for a quick ad hoc refresher\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eBrilliant\u003c\/strong\u003e \"Excellent read with brilliant illustrations. I enjoyed. I would recommend this book for students who have difficulties with understanding statistical concepts in medicine as they are explained clearly\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eFive Stars\u003c\/strong\u003e \"Love the simple way things are explained\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eExcellent book. Easy to understand\u003c\/strong\u003e \"Highly recommend for doctors\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eHelpful\u003c\/strong\u003e \"Helpful book, breaks statistics down into more manageable and less daunting chunks, includes information on how important each point is and how often it is used in real life. I am using it to study for an exam and it is very helpful. The title doesn't lie!\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eExcellent study guide for a \"principle-of\"-Med.-stats type of exams\u003c\/strong\u003e \"Fantastic book for someone who just needs to learn about the application and principles. (Saved me on an exam ;) ). I love this book.\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eEasy read and understanding\u003c\/strong\u003e \"Highly recommended\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eFive Stars\u003c\/strong\u003e \"For anyone that struggles with statistics, this is an absolute must.\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eFive Stars\u003c\/strong\u003e \"Really helpful for AKT exam for my MRCGP. Concise and simplified!\" \u003cem\u003eAmazon reviewer\u003cbr\u003e \u003c\/em\u003e\u003cbr\u003e \u003cstrong\u003eEasy to read\u003c\/strong\u003e \"Gives the basics. Easy to flick through and find what you need. Great book\" \u003cem\u003eAmazon reviewer\u003c\/em\u003e\u003cbr\u003e \u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003cstrong\u003eGreat Medicine Book\u003c\/strong\u003e\u003cbr\u003e ‘Great medicine book. Must have' \u003cem\u003e Amazon reviewer\u003c\/em\u003e \u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003cstrong\u003eCan’t live without\u003c\/strong\u003e\u003cbr\u003e ‘Amazing book for stats. Get it !' \u003cem\u003e Amazon reviewer\u003c\/em\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eStatistics which describe data:\u003c\/b\u003e Percentages; Mean; Median; Mode; Standard deviation\u003cbr\u003e \u003cb\u003e Statistics which test confidence:\u003c\/b\u003e Confidence intervals; \u003ci\u003eP\u003c\/i\u003e values\u003cbr\u003e \u003cb\u003e Statistics which test differences: \u003c\/b\u003e\u003ci\u003et\u003c\/i\u003e tests and other parametric tests; Mann–Whitney and other non-parametric tests; Chi-squared\u003cbr\u003e \u003cb\u003e Statistics which compare risk:\u003c\/b\u003e Risk ratio; Odds ratio; Risk reduction and numbers needed to treat\u003cbr\u003e \u003cb\u003e Statistics which analyze relationships:\u003c\/b\u003e Correlation; Regression\u003cbr\u003e \u003cb\u003e Statistics which analyze survival:\u003c\/b\u003e Survival analysis: life tables and Kaplan–Meier plots; The Cox regression model\u003cbr\u003e \u003cb\u003e Statistics which analyze clinical investigations and screening:\u003c\/b\u003e Sensitivity, specificity and predictive value; Level of agreement\u003cbr\u003e \u003cb\u003e Other concepts\u003c\/b\u003e\u003cbr\u003e \u003cb\u003e Statistics at work:\u003c\/b\u003e Means, standard deviations, medians and odds ratios; Confidence intervals and number needed to treat; Correlation and regression; Survival analysis; Sensitivity, specificity and predictive values; Choosing the right statistical test","brand":"Scion Publishing Ltd","offers":[{"title":"Default Title","offer_id":48868981145943,"sku":"9781911510635","price":20.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781911510635.jpg?v=1722290666"},{"product_id":"physical-therapy-for-intervertebral-disk-disease-a-practical-guide-to-diagnosis-and-treatment-9783131997616","title":"Physical Therapy for Intervertebral Disk Disease:","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePatients with pain emanating from their spines represent some of the most frequent and challenging cases for physical therapists. Here is a comprehensive and practical introduction to the management of back pain and restricted spinal function caused by intervertebral disk damage. The authors provide evidence-based, clinically oriented strategies for the diagnosis and therapeutic treatment of disk injury in the lumbar, thoracic, and cervical spinal regions. The text gives an overview of research studies on the effects of physical therapy on back pain, step-by-step guidance on examination and conservative and postoperative physical therapy procedures, and detailed discussion of rehabilitation and prevention of further disk damage.\u003c\/p\u003e \u003cp\u003e\u003cstrong\u003eKey Features:\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eExtensive coverage of examination, from patient history to tests for assessing spinal movement to nerve conduction\u003c\/li\u003e\n\u003cli\u003ePrecise instructions and useful pointers on treatment methods aid in daily practice\u003c\/li\u003e\n\u003cli\u003eChapter on basic principles of anatomy, physiology, and epidemiology offer foundational knowledge\u003c\/li\u003e\n\u003cli\u003eCrucial information on approaches for rehabilitation and injury prevention, including strengthening, coordination exercises, and conditioning\u003c\/li\u003e\n\u003cli\u003eCase studies present clinical examples that guide the reader through the full course of therapy\u003c\/li\u003e\n\u003cli\u003e70 clear line drawings illustrate how to maintain correct posture; avoid poor posture; and protect and train muscles, nerves, and joints\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ccite\u003ePhysical Therapy for Intervertebral Disk Disease\u003c\/cite\u003e is a complete guide to the diagnosis and physiotherapeutic treatment of problems resulting from intervertebral disk damage. Practitioners and students of physical therapy, rehabilitation medicine, and occupational therapy will read this book cover to cover and refer to it regularly when working to relieve back pain and restore full capacity in their patients.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1: Introduction\u003cbr\u003e Chapter 2: General Principles\u003cbr\u003e Chapter 3: Medical Diagnosis and Treatment\u003cbr\u003e Chapter 4: Diagnosis in Physical Therapy\u003cbr\u003e Chapter 5: Therapy\u003cbr\u003e Chapter 6: Lumbar Spine\u003cbr\u003e Chapter 7: Thoracic Spine\u003cbr\u003e Chapter 8: Cervical Spine\u003cbr\u003e Chapter 9: Rehabilitation and Prevention\u003cbr\u003e Chapter 10: Diseases Occurring in Association With Prolapsed Disks\u003cbr\u003e Chapter 11: Psychosocial Risk Factors\u003cbr\u003e Chapter 12: Selected Studies on the Topic of Spinal Disorders\u003cbr\u003e Chapter 13: Significance, Types, and Objectives of Clinical Studies\u003c\/p\u003e","brand":"Thieme Publishing Group","offers":[{"title":"Default Title","offer_id":48869375672663,"sku":"9783131997616","price":65.08,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783131997616.jpg?v=1722292447"},{"product_id":"silent-invasion-9780063204232","title":"Silent Invasion","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eEarnest and exhaustive. — New York Times Book Review  The best account we have so far of how Trump’s team botched the pandemic response so badly. . . . Significant . . . the book that should be an indispensable resource for future historians. . . . Deborah Birx offers more detail and nuance than anyone else. — The Atlantic  There’s an underappreciated quiet heroism in the steadfast bureaucrat who day after day, for months on end, insists on seeking and spreading the truth. With Silent Invasion, Birx shows us she is a person of extraordinary tenacity who, armed with sound data and a deep sense of duty, fought corrupt forces to save lives as best she knew how. — Washington Post  In-depth...In Silent Invasion, Birx reveals just how untenable her position was and, more importantly, what changes need to happen in order to win against the COVID-19 pandemic.\" — People","brand":"HarperCollins Publishers Inc","offers":[{"title":"Default Title","offer_id":48883779862871,"sku":"9780063204232","price":19.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780063204232.jpg?v=1722529011"},{"product_id":"health-measurement-scales-9780192869487","title":"Health Measurement Scales","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eHealth Measurement Scales is the ultimate guide to appraising, developing, and validating measurement scales that are used in the health sciences. Written in a clear and practical style, this guide enables clinicians and researchers to both develop scales to measure subjective states and non-tangible health outcomes, as well as evaluate and differentiate among existing tools.Topics presented in the order that scales are constructed: how the individual items are developed, biases that can affect responses, various response options, how to select the best items in the set, how to combine them into a scale; and finally how to determine the reliability and validity of the scale.Fully updated to reflect recent developments in the field and the latest survey methods. The new edition contains updated information on generalizability theory and item response theory, and integration of qualitative research methods into scale design and testing. Including guidelines, appendices and checklists, this useful book is a must-read for any practitioner dealing with any kind of subjective measurement.","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48883828719959,"sku":"9780192869487","price":40.84,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780192869487.jpg?v=1722529212"},{"product_id":"measuring-health-a-review-of-subjective-health-wellbeing-and-quality-of-life-measurement-scales-9780335261949","title":"Measuring Health A Review of Subjective Health","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eAn invaluable resource for health professionals and students engaged in research, this thoroughly updated edition provides a guide to the major measures of health and functioning.\u003cbr\u003e \u003cbr\u003eMeasures of subjective health, well-being and quality of life are introduced along with analysis of their validity and reliability and the evidence for using each one. Throughout the book each measure is explained with a summary of how each one is scored and used, making this a one-stop guide to understanding health measurements, and the basic concepts behind measuring health, quality of life and well-being. \u003cbr\u003e\u003cbr\u003eâ A new look and feel makes measures and scales easier to locate\u003cbr\u003eâ Further research and evidence provides a greater critique of the measures \u003cbr\u003eâ Useful source information to help you access each measure with permission\u003cbr\u003eâ The addition of new scales include the Warwick-Edinburgh Wellbeing Scale, the Older Peopleâs Quality of Life Scale and the Short-Form McGill\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eConcepts Of Functioning And Health, Well-Being And Quality Of Life\u003cbr\u003eTheory Of Measurement\u003cbr\u003eMeasuring Functional Ability\u003cbr\u003eMeasuring Broader Health Status\u003cbr\u003eMeasuring Psychological Well-Being\u003cbr\u003eMeasuring Social Networks And Social Support\u003cbr\u003eMeasuring The Dimensions Of Subjective Well-Being\u003cbr\u003eMeasuring  Broader Quality Of Life\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003cbr\u003e \u003c\/p\u003e","brand":"Open University Press","offers":[{"title":"Default Title","offer_id":48884003701079,"sku":"9780335261949","price":35.14,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780335261949.jpg?v=1722529990"}],"url":"https:\/\/bookcurl.com\/collections\/epidemiology-and-medical-statistics.oembed?page=14","provider":"Book Curl","version":"1.0","type":"link"}